

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The yield of bronchoscopy in the diagnosis of lung diseases.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-043820
Article Type:	Original research
Date Submitted by the Author:	14-Aug-2020
Complete List of Authors:	Błach, Justyna; Medical University of Lublin, Frąk, Małgorzata; Medical University of Lublin Krawczyk, Pawel; Medical University of Lublin Pankowski, Juliusz; Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska Pankowski, Adam; SilverSoft Buczowski, Jarosław; Medical University of Lublin Szlubowski, Artur; Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska Siwiec, Jan; Medical University of Lublin Krudysz, Piotr; Izer-Med Michnar, Marek; Medical University of Lublin Kieszko, Robert; Medical University of Lublin Milanowski, Janusz; Medical University of Lublin
Keywords:	Bronchoscopy < THORACIC MEDICINE, Respiratory tract tumours < ONCOLOGY, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The yield of bronchoscopy in the diagnosis of lung diseases

Justyna Błach^{1,2*}, Małgorzata Frąk^{1*}, Paweł Krawczyk¹, Juliusz Pankowski³, Adam Pankowski⁴, Jarosław Buczkowski^{1,5}, Artur Szlubowski^{3,6}, Jan Siwiec¹, Piotr Krudys⁶, Marek Michnar¹, Robert Kieszko¹, Janusz Milanowski¹

* authors equally contributing

1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-954 Lublin; Poland
2. Department of Clinical Immunology, Medical University of Lublin, 20-954 Lublin; Poland
3. Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska, 34-500 Zakopane, Poland
4. SilverSoft, Warszewska 64/1, 72-004 Pilchowo, Szczecin, Poland
5. Department of Lung Diseases and Intensive Care, Independent Public Provincial John of God Hospital in Lublin, 20-400 Lublin, Poland
6. Izerski Pulmonology and Chemotherapy Center "IZER-MED", 58-580 Szklarska Poręba, Poland

Short title: **The yield of bronchoscopy in the diagnosis of lung diseases**

Corresponding author:

Justyna Błach MD

Department of Pneumonology, Oncology and Allergology

Medical University of Lublin, Poland

Jaczewskiego 8, 20-954 Lublin, Poland

tel. +48 81 724 42 93

e-mail: justynablach91@gmail.com

Abstract

Introduction

Bronchoscopy is the main method in the diagnosis of various lung diseases. EBUS-TBNA is the most modern bronchoscopic technique useful in diagnosis and staging of lung cancer (LC).

Objectives

The aim of the study was to assess the yield of bronchoscopy in the diagnosis of various respiratory diseases. Especially, we examined the possibility of obtaining diagnostic material using bronchoscopic techniques in patients with various pathomorphological types of LC.

Patients and Methods

The results of pathomorphological examinations from 5279 bronchoscopies performed in 2016-2018 were analyzed. Clinical and demographic factors were analyzed using the Fisher χ^2 test.

Results

5279 patients (1892 women, 3387 men) were diagnosed due to various respiratory symptoms. LC was confirmed in 36.42% of patients, reactive lymph nodes – in 16.06%, sarcoidosis – in 4.12%, IPF – in 0.19%, non-LC metastases – in 2.39%. 40.81% of patients had no definitive diagnosis. SCC was most often diagnosed (32.07%), then AC, (30.61%), SCLC (25.83%) and NSCLC NOS (11.49%). Diagnosis of SCC was obtained significantly more often ($\chi^2=43.143$, $p<0.000001$) by endobronchial (41.09%) than by transbronchial biopsies (26.62%). Diagnosis of AC or NDRP NOS was significantly more often ($\chi^2=20.394$, $p<0.000007$ and $\chi^2=3.902$, $p<0.05$, respectively) observed in transbronchial biopsies (34.31% and 12.6%) than in endobronchial biopsies (24.52% and 9.64%).

Conclusion

The use of bronchoscopy in the diagnosis of various lung diseases has many limitations. SCLC and SCC may be more common in Poland than in other European countries and in US. Effectiveness of EBUS-TBNA and forceps biopsy is strongly affected by tumor localization and type of cancer.

Key words: lung cancer; bronchoscopy; endobronchial biopsy; EBUS-TBNA; EUS-FNA

Article summary

Strengths and limitations of this study

1. This is one of the largest bronchoscopy methods effectiveness research in routine clinical practice.
2. Endobronchial biopsy is more effective in the diagnosis of squamous cell carcinoma (central tumors). Whereas, EBUS-TBNA and EUS-FNA has higher efficiency in the detection of adenocarcinoma (peripheral tumors).
3. Study shows that advanced small cell lung cancer may be underestimated.
4. The study revealed that EBUS-TBNA value in daily clinical practice differed from that in clinical trials.
5. It was not possible to determine the final diagnosis for all patients in this large group (5279 cases). Not distinguish between material collected by EBUS-TBNA and EUS-FNA. The lack of detailed clinical and radiological characteristics of all patients who underwent the bronchoscopy procedures.

Introduction

Epidemiological analyses indicate that lung cancer (LC) is the most common cause of cancer-related death. It is usually diagnosed in an unresectable, advanced stage. [1, 2] LC is the most common cancer in men and the third most common in women. In 2018, there were more than 2 million new cases of lung cancer worldwide. [3]

In the United States from 2004 to 2009, a total of 1,096,276 lung cancer cases were diagnosed and reported. This American study investigated the histologic type of lung cancer and demographic characteristics of the patients. The incidence of individual types of LC was as follows: small cell lung cancer (SCLC) – 14.9% of cases, squamous cell carcinoma (SCC) – 21.9% of cases, adenocarcinoma (AC) – 37.1% of cases and large cell carcinoma (LCC) – 3.2% of patients. [4]

It is difficult to obtain accurate epidemiological data on the occurrence of individual pathomorphological types of LC in advanced stages. Such data is only available on patients undergoing surgery in earlier stages of the disease. 17,783 patients diagnosed and operated in

1
2
3 Polish thoracic surgery centers were registered in the National Lung Cancer Registry in the
4 years 2014-2018. This group includes: 48.7% of patients with AC, 40.8% of patients with
5 SCC, 6.45% of patients with LCC, 2.1% of patients with adenosquamous cell carcinoma,
6 1.05% of patients with SCLC and 0.9% of patients with non-otherwise specified (NOS) non-
7 small cell lung cancer (NSCLC). This material included a low percentage of patients with
8 SCLC (usually an inoperable type of lung cancer) and patients with NSCLC-NOS (large
9 surgical material is easy for pathomorphological examination). In addition, LCC should be
10 diagnosed only in the surgical material. Therefore, this type of cancer is almost absent in
11 patients with advanced lung cancer (it could not be diagnosed in the small specimens). [2]

12
13
14
15
16
17
18
19 Due to different locations and tumor types, varied approaches are required to cancer
20 diagnosis in different compartments of the lung or metastatic lymph nodes. Bronchoscopy is
21 an appropriate method for detecting LC. Endobronchial ultrasound-guided with transbronchial
22 needle aspiration (EBUS-TBNA) and endoscopy ultrasound with fine needle aspiration (EUS-
23 FNA) are preferred for mediastinal lymph nodes assessment for evaluation of N-stage in
24 patients with NSCLC. [5] However, endobronchial forceps biopsy or cryobiopsy may be
25 preferred mainly in diagnosis of the central tumors. These two methods could be used in
26 sampling visible tumors localized in central airways but also peripherally to the main bronchi,
27 i.e. in lobar or even segmental bronchi. The sensitivity of detecting lung cancer by
28 bronchoscopy varies from 34% to 88% depending on the size and location of the tumor and
29 preliminary diagnosis of the patients. [6] Meta-analysis of 18 studies which included a total of
30 1,201 patients with LC diagnosed by ultrasound-guided fine needle aspiration showed
31 sensitivity of 83% (range 45-100%) and specificity of 97% (range 88-100%) of these
32 methods. [7] However, all false negative results delay cancer diagnosis and force the
33 repetition of diagnostic procedures including surgery. While, earlier detection of the lung
34 cancer gives patients the chance for better treatment. [8]

35 36 37 38 39 40 41 42 43 44 45 46 **Aim**

47
48 The aim of our study was to assess the yield of bronchoscopy in the diagnosis of
49 different lung diseases in daily clinical practice. Especially, we devoted special attention to
50 the possibility of diagnosis of individual pathomorphological types of LC with various
51 techniques use for collecting materials during bronchoscopy.

52 53 54 55 **Material and methods**

56
57 In our observational cross-sectional study, we analyzed the results of
58 pathomorphological examination carried out on the material obtained by the 5279
59 bronchoscopies performed in 2016-2018. Those bronchoscopies were performed in three
60

1
2
3 Polish pulmonology departments. The study included 1892 women and 3387 men with
4 median age of 65 years.

5
6 Various diseases of the respiratory system were indication for bronchoscopy: 3127
7 (59.2%) patients had suspicion of chest tumor in computed tomography, 882 (16.7%) patients
8 demonstrated hilar lymphadenopathy, 205 (3.9%) patients had suspicion of sarcoidosis and 20
9 (0.4%) patients had suspicion of pulmonary fibrosis. Other indications for bronchoscopy
10 occurred in 1045 (19.8%) patients (e.g. suspicion of tuberculosis, chronic cough, hemoptysis,
11 etc.). After receiving the diagnosis, we selected a population of patients with lung cancer and
12 divided them to groups of patients with different cancer types (squamous cell lung cancer,
13 adenocarcinoma, large cell carcinoma, not otherwise specified NSCLC and small cell lung
14 cancer). Then we assessed the prevalence of different types of LC in the materials obtained
15 with various bronchoscopic procedures.

16
17 In 3565 (67.5%) patients, EBUS-TBNA and EUS-FNA was performed and
18 cytological material archived in a cytoblock was obtained. In 1346 (25.5%) patients, EBUS-
19 TBNA (without EUS-FNA) was the only diagnostic procedure. In the remaining patients,
20 EBUS-TBNA was supplemented by EUS-FNA. There were no patients in whom EUS-FNA
21 would be the only diagnostic method. 1714 (32.5%) patients had non-ultrasound-guided
22 bronchoscopy with the forceps biopsy of endobronchial lesions allowing to obtain a small
23 histological specimen. The method for tissue sampling was chosen based on the location of
24 the lesions and mediastinal or hilar lymph node status. Forceps biopsies were performed using
25 Olympus BF-1T180 and Pentax EB-1970K bronchoscopes, EBUS-TBNA – using Olympus
26 BF-UC180F and Pentax EB-1970UK bronchoscopes (22-gauge needles), and EUS-FNA –
27 using Olympus GF-UCT180 endoscope. Premedication for bronchoscopy was under local or
28 general anesthesia, depending on the situation.

29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Statistical analysis

Clinical and demographic factors were analyzed using the Pearson's Chi-square test. P-values below 0.05 were considered significant. The percentages reflect the relative number of all lung cancer patients diagnosed with a particular procedure. The evaluation of relative diagnostic yield (sensitivity) of different bronchoscopic procedures could not be done because, in our study, it was not possible to verify the final diagnosis of analyzed patients. We only analyzed the results of the first-time bronchoscopy. Further diagnostic procedures were often not performed in our clinical centers. The following diagnostic procedures were carried out in various clinical centers throughout Poland.

Ethics approval

1
2
3 The protocol of the study was approved by the Committee of Ethics and Research at the Medical
4 University of Lublin (KE-0254/5/2018).

6 Results

7
8 Lung cancer was confirmed in group of 1923 (36.42%) patients, including 1280 men
9 and 643 women. Only reactive lymph nodes were found in 16.06% of the patients, sarcoidosis
10 was diagnosed in 4.13% of the patients, idiopathic pulmonary fibrosis – in 0.19% of the
11 patients, metastases to the lungs from other organs – in 2.39% of the patients. 40.81% of the
12 patients had no definitive diagnosis (Figure 1). Lung cancer was confirmed in 51% of patients
13 with suspected tumor in computed tomography. While, in the group of patients with hilar
14 lymphadenopathy, lung cancer was diagnosed in only 10.1% of cases.

15
16 Among patients with lung cancer, squamous cell carcinoma (32.07%) was most often
17 diagnosed, then adenocarcinoma (30.61%), small cell lung cancer (25.83%) and NSCLC-
18 NOS (11.49%) (Figure 2). SCLC and AC were significantly more frequent ($\chi^2 = 8.649$, $p =$
19 0.0033 and $\chi^2 = 21.128$, $p < 0.000005$, respectively) in women (29.97% and 37.42% of
20 women with lung cancer) than in men (23.75% and 27.19% of male patients with lung
21 cancer). Squamous cell carcinoma appeared significantly more often ($\chi^2 = 41.881$, $p <$
22 0.000001) among male (36.95%) than among female (22.36%) patients with lung cancer
23 (Figure 3). SCC was significantly more often ($\chi^2 = 4.17$, $p = 0.041$) diagnosed in the group of
24 patients older than 65 years than in younger patients. Other pathomorphological types of lung
25 cancer occurred with similar frequency in these two age groups.

26
27 Endobronchial biopsies significantly more often ($\chi^2 = 7.566$, $p = 0.0059$) provided
28 material for the diagnosis of lung cancer than the EBUS-TBNA and EUS-FNA procedures.
29 42.35% of endobronchial biopsies and 33.6% of transbronchial and transesophageal biopsies
30 provided material sufficient to diagnose lung cancer. Fine needle biopsy of lymph nodes
31 enabled the diagnosis of lung cancer in 29.2% of cases, fine needle biopsy of lung tumor – in
32 66.6% of cases, and forceps biopsy of bronchial mucosa lesions – in 48.2% of cases. These
33 differences were statistically significant.

34
35 Among patients with lung cancer, transbronchial or transesophageal biopsies
36 compared to endobronchial biopsies were similarly effective ($\chi^2 = 0.656$, $p = 0.418$) in
37 detecting SCLC (26.5% vs. 24.8%). On the other hand, the diagnosis of AC and NSCLC-
38 NOS was obtained significantly more frequently ($\chi^2 = 20.394$, $p = 0.000006$ and $\chi^2 = 3.902$, p
39 $= 0.0482$) in EBUS-TBNA and EUS-FNA compared to endobronchial biopsies (34.3% vs.
40 24.52% and 12.6% vs. 9.6%, respectively). SCC was significantly more often ($\chi^2 = 43.143$, p
41 < 0.000001) diagnosed in material obtained from forceps biopsy than in material from EBUS-
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 TBNA and EUS-FNA (41.09% vs 26.62%) (Figure 4). Table 1 shows the effectiveness of
4 bronchoscopy in the diagnosis of individual pathomorphological types of lung cancer
5 depending on place of collecting the material.
6
7

8 **Discussion**

9

10 Our study on the yield of EBUS-TBNA and forceps biopsy in obtaining material for
11 the diagnosis of various lung diseases is among the largest worldwide. The study points to
12 numerous problems arising from the use of these techniques in routine clinical practice. We
13 are aware of the many limitations of our study. First, we cannot determine the sensitivity and
14 specificity of our methods, because it was not possible to determine the final diagnosis in this
15 large group of patients (5279 cases). In addition, we could not distinguish between material
16 collected by EBUS-TBNA and EUS-FNA. Thirdly, diagnosis of large cell carcinoma was not
17 possible in small specimens (LCC was probably qualified to the NSCLC-NOS group). A
18 limitation of our study was also the lack of detailed clinical and radiological characteristics of
19 all patients who underwent the bronchoscopy procedures.
20
21
22
23
24
25
26

27 However, we found that advanced small cell lung cancer may be more common in
28 Poland than previously thought. This tumor is characterized by rapid growth and metastases,
29 therefore, more often it could be diagnosed in advanced stages using bronchoscopic
30 techniques. USG-guides transbronchial biopsy of lymph nodes and endobronchial biopsy had
31 similar efficiency in SCLC detection. Furthermore, the difference in the percentage of patients
32 with squamous cell carcinoma and adenocarcinoma diagnosed with endo- and transbronchial
33 biopsies is noteworthy. In our study, most patients with adenocarcinoma were diagnosed with
34 EBUS-TBNA or EUS-FNA of lymph nodes, while patients with squamous cell carcinoma
35 were diagnosed more often based on examination of material from endobronchial biopsy
36 (forceps biopsy). Endobronchial biopsy is more effective in the diagnosis of squamous cell
37 carcinoma, because patients often had a centrally located tumor. Thus, we point to the
38 problem that effective bronchoscopic procedures depends on the location of the primary
39 tumor and the presence of metastases in the lymph nodes.
40
41
42
43
44
45
46
47
48
49

50 Schmid-Bindert et al. performed prospective study in group of 106 patients with
51 NSCLC diagnosis. Small biopsies were collected by three different methods: forceps biopsy
52 (44.6%), EBUS-TBNA (32.7%), and CT-guided core biopsy (22.8%). 38% of
53 adenocarcinoma, 51% of squamous cell carcinoma and 11% of NSCLC-NOS were diagnosed
54 using forceps biopsy. EBUS-TBNA results were 45% for adenocarcinoma, 30% for squamous
55 cell carcinoma and 24% for NSCLC-NOS. [9]
56
57
58
59
60

1
2
3 Many authors emphasize that the diagnosis of NSCLC-NOS is the most common in
4 the case of material obtained from EBUS-TBNA. Esterbrook et al. found that NSCLC-NOS
5 rate was 20.8% in EBUS-TBNA samples. Similar results were received by Navani et al. In
6 group of 774 patients with known or suspected lung cancer, 23% of patients had a final
7 diagnosis of NSCLC-NOS. [10, 11]
8
9

10
11 Chin et al. reported that EBUS-TBNA is the most sensitive diagnostic methods for
12 SCLC, because it allows to sample of specimens from mediastinal as well as submucosal
13 lesions. They also mentioned that the quality of specimens obtained by needle aspiration is
14 better than by forceps biopsies, which may contain crush artifacts. [12] In addition, other
15 studies noticed that the sensitivity of EBUS-TBNA for SCLC detection was higher than for
16 NSCLC diagnosis. [13, 14]
17
18

19
20 Many authors raise the problem that forceps biopsy has low sensitivity in the diagnosis
21 of lung cancer. Forceps biopsy has a diagnostic yield ranging between 65-82% [15, 16]. In
22 our preliminary study conducted in 212 patients with lung cancer suspicion, we compared
23 sensitivity and accuracy of routine bronchoscopy with endobronchial biopsy, EBUS-TBNA,
24 and combination of EBUS-TBNA and EUS-FNA techniques. Sensitivity and accuracy of
25 endobronchial biopsy vs EBUS-TBNA vs combination of transbronchial biopsies were 43%
26 vs 44.3% vs 93.7% and 93.8% vs 94.7% and 94.8%, respectively. This demonstrates high
27 usefulness of the combination of EBUS-TBNA and EUS-FNA in the diagnosis of lung cancer
28 [17]. Verma et al. demonstrated sensitivity of EBUS-TBNA in cancer diagnosis of 91.4% in
29 small group of 37 patients with lesions located adjacent to the trachea or lesions located
30 adjacent to the main bronchi. [18] Tournoy et al. indicated that EBUS-TBNA has a sensitivity
31 of 82% and low negative predictive value (23%). [19] The similar results received Zhao et al.
32 for lesions located near the central airways. [20] Oki et al. showed that the combined
33 endoscopic method with EBUS-TBNA and EUS-FNA with a single bronchoscope gives
34 better results in staging of NSCLC than each technique alone. However, they mentioned that
35 significant number of patients had false-negative EBUS-TBNA and EUS-FNA results.
36 Moreover Oki et al. suggested that very important issue is bronchoscopists experience, which
37 may cause differences in the results. [21] On the other hand, Wallace et al. showed a EBUS-
38 TBNA sensitivity of only 69% in a group of 150 patients with lung cancer suspicion. [22]
39
40 Despite relatively low negative predictive value of EBUS-TBNA, there is an
41 indication to perform other procedures (e.g. surgical procedures) for final diagnosis in a
42 significant group of patients. In our study, 56.9% of patients who underwent bronchoscopy
43 did not receive a definitive diagnosis of the diseases and they have been subjected to other
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 diagnostic procedures or observations. We showed the results of all performed
4 bronchoscopies and three different method of material collection (endobronchial biopsy and
5 combination EBUS-TBNA and EUS-FNA). Moreover, unselected and heterogeneous patient
6 population were recruited in three different hospitals that employ a total of 8 bronchoscopists.
7
8 In most studies, the evaluation of the usefulness of EBUS-TBNA and EUS-FNA for detecting
9 malignancy was conducted in selected patients with high clinical suspicion of the tumor.
10
11 Small, preselected groups of patients with high risk of lung cancer could be the reason of the
12 low negative predictive value of bronchoscopic procedures in these studies. Thus, these
13 observation may not reflected the real clinical situation.
14
15
16
17
18

19 In studies where population was heterogenic regarding the disease (lung cancer,
20 sarcoidosis, tuberculosis), EBUS-TBNA had diagnostic value only in 60-75% of patients. [23]
21 Lange et al. showed diagnostic results of EBUS-TBNA in only 61.4% of unselected patients
22 undergoing routine diagnostic procedures. [24] Fournier et al. examined 185 patients with
23 extrathoracic malignancy and mediastinal lymphadenopathy in real life practice.
24 Pathomorfological types of malignancy were successfully identified using EBUS-TBNA in
25 only 93 patients (50.3%). The diagnostic sensitivity, specificity, negative predictive value,
26 and positive predictive value were 68.4%, 100%, 53.3%, and 100%, respectively. [25]
27
28
29
30
31

32 **Conclusions**

33
34 Comparing all these data we could conclude that bronchoscopy is not an ideal
35 technique in the routine diagnosis of respiratory diseases. Our study proved that 41%
36 bronchoscopy material was insufficient to perform reliable pathomorphological examination.
37 This mainly concerned patients with suspected lung tumor or lymphadenopathy. Especially,
38 here is a problem in the diagnosis of advanced lung tumors (mainly adenocarcinomas) using
39 bronchoscopy if it is performed as the only procedure. We found that the EBUS-TBNA value
40 in daily clinical practice differed from that in clinical trials. Therefore, precise estimation of
41 the frequency of individual pathomorphological types of lung cancer based on material
42 obtained bronchoscopically is not possible. It seems that the incidence of lung cancer with a
43 typical peripheral localization (adenocarcinoma) may be underestimated in comparison to the
44 incidence of lung cancer with a typical central localization (squamous cell carcinoma, SCLC).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Authorship contribution statement:

Conception and design of the study: JB, MF, PK, JP. Administrative support: PK, JP, AP, JB, AS, JS, MM, PK, RK, JM. Provision of study material or patients: JP, AP, JB, AS, JS, MM, PK, RK, JM. Collection and assembly of data: JB, MF, PK, JP, AP, JB, AS, JS, MM, PK, RK. Data analysis and interpretation: JB, MF, PK. Manuscript writing: JB, MF, PK. All authors gave final approval of the published manuscript.

Data Availability Statement:

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest:

The authors declare no potential conflicts of interest.

Foundings:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgements:

The authors would like to thank prof. Tadeusz Orłowski and prof. Maciej Krzakowski for their helpful comments that improved the research and manuscript.

References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. *CA Cancer J Clin.* 2017; 67: 7-30.
2. Travis WD, Brambilla E, Burke AP, et al. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. *Thorac Oncol.* 2015; 10: 1240-1242.
3. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018; 68: 394-424.
4. Houston KA, Henley SJ, Li J, et al. Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009. *Lung Cancer.* 2014; 86: 22-28.
5. Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer. *European Society of*

- 1
2
3 Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European
4 Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). *Eur*
5 *Respir J*. 2015; 46: 40-60.
6
7
8
9 6. Rivera MP, Wahidi MM, Mehta AC. Establishing the diagnosis of lung cancer: Diagnosis
10 and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-
11 based clinical practice guidelines. *Chest*. 2013; 143: 142-165.
12
13 7. Micames CG, McCrory DC, Pavey DA, et al. Endoscopic ultrasound-guided fine-needle
14 aspiration for non-small cell lung cancer staging: A systematic review and meta-analysis.
15 *Chest*. 2007. 131: 539–548.
16
17 8. Sutedja TG, Codrington H, Risse EK, et al. Autofluorescence bronchoscopy improves
18 staging of radiographically occult lung cancer and has an impact on therapeutic strategy.
19 *Chest*. 2001. 120: 1327-1332.
20
21 9. Schmid-Bindert G, Wang Y, Jiang H, et al. EBUS-TBNA provides highest RNA yield for
22 multiple biomarker testing from routinely obtained small biopsies in non-small cell lung
23 cancer patients - a comparative study of three different minimal invasive sampling
24 methods. *PLoS One*. 2013; 8: 77948.
25
26 10. Navani N, Brown JM, Nankivell M, et al. Suitability of EBUS-TBNA specimens for
27 subtyping and genotyping of NSCLC: a multi-centre study of 774 patients. *Am J Respir*
28 *Crit Care Med*. 2012; 185: 1316-1322.
29
30 11. Esterbrook G, Anathhanam S, Plant PK. Adequacy of endobronchial ultrasound
31 transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer.
32 *Lung Cancer*. 2013; 80: 30–34.
33
34 12. Chin R Jr, Cappellari JO, McCain TW, et al. Increasing use of bronchoscopic needle
35 aspiration to diagnose small cell lung cancer. *Mayo Clin Proc*. 2000; 75: 796-801.
36
37 13. Fernandez-Villar A, Botana M, Leiro V, et al. Validity and reliability of transbronchial
38 needle aspiration for diagnosing mediastinal adenopathies. *BMC Pulm Med*. 2010; 10: 24.
39
40 14. Sharafkhaneh A, Baaklini W, Gorin AB, et al. Yield of transbronchial needle aspiration in
41 diagnosis of mediastinal lesions. *Chest*. 2003; 124: 2131-2135.
42
43 15. Rivera MP, Mehta AC. American College of Chest Physicians. Initial diagnosis of lung
44 cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest*. 2007; 132:
45 131–148.
46
47 16. Rivera MP, Detterbeck F, Mehta AC. American College of Chest Physicians. Diagnosis of
48 lung cancer: the guidelines. *Chest*. 2003; 123: 129–136.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
17. Pasko E, Serafin-Bromblik J, Piekorz W, et al. Combined endobronchial and endoscopic ultrasound-guided needle aspiration performed by single ultrasound bronchoscopes routine videobronchoscopy for diagnosis of advanced lung cancer – a prospective study. *Eur Respir J*. 2016; 48: 2034.
 18. Verma A, Jeon K, Koh WJ, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of central lung parenchymal lesions. *Yonsei Med J*. 2013; 54: 672–678.
 19. Tournoy KG, Rintoul RC, van Meerbeeck JP, et al. EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. *Lung Cancer*. 2009; 63: 45-49.
 20. Zhao H, Xie Z, Zhou ZL, et al. Diagnostic value of endobronchial ultrasound-guided transbronchial needle aspiration in intrapulmonary lesions. *Chin Med J*. 2013; 126: 4312-4315.
 21. Oki M, Saka H, Ando M, et al. Endoscopic ultrasound-guided fine needle aspiration and endobronchial ultrasound-guided transbronchial needle aspiration: Are two better than one in mediastinal staging of non–small cell lung cancer? *J Thorac Cardiovasc Surg*. 2014; 148: 1169-1177.
 22. Wallace MB, Pascual JM, Raimondo M, et al. Minimally invasive endoscopic staging of suspected lung cancer. *JAMA*. 2008; 299: 540-546.
 23. Madan K, Mohan A, Ayub II, et al. Initial experience with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) from a tuberculosis endemic population. *J Bronchol Interv Pulmonol*. 2014; 21: 208–214.
 24. Lange T, Kunzendorf F, Pfeifer M, et al. Endobronchial ultrasound-guided transbronchial needle aspiration in routine care-plenty of benign results and follow-up tests. *Int J Clin Pract*. 2012; 66: 438–445.
 25. Fournier C, Hermant C, Gounant V, et al. Diagnostic of mediastinal lymphadenopathy in extrathoracic cancer: a place for EBUS-TBNA in real life practice? *Respir Med Res*. 2019; 75: 1–4.

53
54
55
56

Table 1. The effectiveness of bronchoscopy in the diagnosis of individual pathomorphological types of lung cancer depending on place of collecting the material and nodal station.

Material	SCLC	Adenocarcinoma	Squamous cell carcinoma	NOS	Total lung cancer

EBUS-TBNA/EUS-FNA of lymph nodes	250 (27.7%)	331 (36.7%)	209 (23.1%)	114 (12.5%)	904 (100%)
EBUS-TBNA/EUS-FNA of tumor	88 (24.7%)	94 (25.8%)	135 (37.2%)	44 (12.3%)	361 (100%)
EBUS-TBNA/EUS-FNA metastases to adrenal gland	3 (42.9%)	1 (14.3%)	2 (28.6%)	1 (14.3%)	7 (100%)
Forceps biopsy of tumor	156 (22%)	163 (25%)	270 (41.5%)	62 (9.5%)	651 (100%)

Figure 1. Results of pathomorphological examination carried out on material obtained from 5279 bronchoscopies (entire study population)

Figure 2. The incidence of individual pathomorphological types of LC in the entire study group of lung cancer patients

Figure 3. The incidence of individual pathomorphological types of LC according to the gender of patients with lung cancer

Figure 4. Percentage of patients with different types of lung cancer detected in materials collected with different bronchoscopic techniques. Frequency of different types of lung cancer was calculated in the whole group of patients undergoing a given bronchoscopic procedure (100%), which resulted in the diagnosis of lung cancer

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Results of pathomorphological examination carried out on material obtained from 5279 bronchoscopies (entire study population)

108x60mm (300 x 300 DPI)




Figure 2. The incidence of individual pathomorphological types of LC in the entire study group of lung cancer patients

296x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. The incidence of individual pathomorphological types of LC according to the gender of patients with lung cancer

296x209mm (300 x 300 DPI)




Figure 4. Percentage of patients with different types of lung cancer detected in materials collected with different bronchoscopic techniques. Frequency of different types of lung cancer was calculated in the whole group of patients undergoing a given bronchoscopic procedure (100%), which resulted in the diagnosis of lung cancer

296x209mm (300 x 300 DPI)

BMJ Open

The analysis of 5279 bronchoscopy results for the efficiency of various biopsy techniques in the diagnosis of lung cancer

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-043820.R1
Article Type:	Original research
Date Submitted by the Author:	28-Feb-2021
Complete List of Authors:	Błach, Justyna; Medical University of Lublin, Frąk, Małgorzata; Medical University of Lublin Krawczyk, Pawel; Medical University of Lublin Pankowski, Juliusz; Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska Pankowski, Adam; SilverSoft Buczowski, Jarosław; Medical University of Lublin Szlubowski, Artur; Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska Siwiec, Jan; Medical University of Lublin Krudysz, Piotr; Izer-Med Michnar, Marek; Medical University of Lublin Kieszko, Robert; Medical University of Lublin Milanowski, Janusz; Medical University of Lublin
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Oncology
Keywords:	Bronchoscopy < THORACIC MEDICINE, Respiratory tract tumours < ONCOLOGY, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **The analysis of 5279 bronchoscopy results for the efficiency of various biopsy techniques**
4 **in the diagnosis of lung cancer**
5
6
7

8 Justyna Błach^{1,2*}, Małgorzata Frąk^{1*}, Paweł Krawczyk¹, Juliusz Pankowski³, Adam
9 Pankowski⁴, Jarosław Buczkowski^{1,5}, Artur Szlubowski^{3,6}, Jan Siwiec¹, Piotr Krudys⁶, Marek
10 Michnar¹, Robert Kieszko¹, Janusz Milanowski¹
11
12

13 * authors equally contributing
14
15
16

17 1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin,
18 20-954 Lublin; Poland
19

20 2. Department of Clinical Immunology, Medical University of Lublin, 20-954 Lublin; Poland
21

22 3. Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska, 34-500 Zakopane, Poland
23

24 4. SilverSoft, Warszewska 64/1, 72-004 Pilchowo, Szczecin, Poland
25

26 5. Department of Lung Diseases and Intensive Care, Independent Public Provincial John of
27 God Hospital in Lublin, 20-400 Lublin, Poland
28

29 6. Izerski Pulmonology and Chemotherapy Center "IZER-MED", 58-580 Szklarska Poręba,
30 Poland
31
32

33
34
35
36
37
38
39 **Short title: The yield of bronchoscopy in the diagnosis of lung cancer**

40 **Corresponding author:**
41

42 Justyna Błach MD
43

44 Department of Pneumonology, Oncology and Allergology
45

46 Medical University of Lublin, Poland
47

48 Jaczewskiego 8, 20-954 Lublin, Poland
49

50 tel. +48 81 724 42 93
51

52 e-mail: justynablach91@gmail.com
53
54
55
56
57
58
59
60

Abstract

Introduction

Bronchoscopy is the main method in the diagnosis of various lung diseases. Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is the most modern bronchoscopic technique useful in diagnosis and staging of lung cancer.

Objectives

The aim of the study was to assess the yield of bronchoscopy in patients with suspected various respiratory diseases including lung cancer. In particular, we examined the efficiency of different biopsy techniques in the diagnosis of lung cancer in correlation with its localization and pathomorphological type.

Patients and Methods

The results of pathomorphological examinations from 5279 bronchoscopies performed in 2016-2018 were analyzed. The material was collected with endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA), endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and endobronchial forceps biopsy. Clinical and demographic factors were analyzed using the Fisher χ^2 test.

Results

5279 patients were diagnosed due to various respiratory symptoms. Lung cancer was confirmed in 36.42% of patients. 40.81% of patients had no definitive pathomorphological diagnosis. Among patients with lung cancer, the most frequent diagnosis was non-small cell lung cancer: squamous cell lung cancer (SCC) - 32.07% and adenocarcinoma (AC) - 30.61%, then small cell lung cancer (SCLC) - 25.83% and not otherwise specified non-small cell lung cancer (NSCLC NOS) - 11.49%. Diagnosis of SCC was obtained significantly more often ($\chi^2=43.143$, $p<0.000001$) by endobronchial (41.09%) than by EBUS-TBNA/EUS-FNA (26.62%). On the contrary, diagnosis of AC or NSCLC NOS was significantly more often ($\chi^2=20.394$, $p<0.000007$ and $\chi^2=3.902$, $p<0.05$, respectively) observed in EBUS-TBNA/EUS-FNA (34.31% and 12.6%) than in endobronchial biopsies (24.52% and 9.64%).

Conclusions

The use of bronchoscopy in the diagnosis of various lung diseases is vital but also has many limitations. Effectiveness of EBUS-TBNA and endobronchial forceps biopsy in diagnosis of lung cancer is strongly affected by tumor localization and type of cancer.

Key words: lung cancer; bronchoscopy; endobronchial biopsy; EBUS-TBNA; EUS-FNA

Article summary

Strengths and limitations of this study

1. 5 279 patients were enrolled to the study group which makes it one of the largest studies in the world with assessment of bronchoscopy effectiveness in routine clinical practice.
2. We analyzed bronchoscopies underwent in 2016-2018 in a few Polish medical centers across the country in diversified population which ensure a high level of generalisability.
3. The study is an important contribution to the epidemiological data of advanced lung cancer in Poland.
4. Bronchoscopies were performed by 8 different bronchoscopists. This fact may cause human-dependent variation in results.
5. Results of pathomorphological assessment of the material obtained during single bronchoscopy was analyzed. Patients without diagnosed disease in the bronchoscopic material underwent further diagnostics using other methods or in other centers. Therefore, we were unable to report a definitive diagnosis in patients with inconclusive results of diagnostic procedures.

Introduction

Epidemiological analyses indicate that lung cancer (LC) is the most common cause of cancer-related death. It is usually diagnosed in an unresectable, advanced stage. [1, 2] Lung cancer is the most common cancer in men and the third most common in women. In 2018, there were more than 2 million new cases of lung cancer worldwide. [3]

In the United States from 2004 to 2009, a total of 1,096,276 lung cancer cases were diagnosed and reported. This American study investigated the histologic type of lung cancer and demographic characteristics of the patients. The incidence of individual types of LC was as follows: small cell lung cancer (SCLC) – 14.9% of cases, squamous cell carcinoma (SCC) – 21.9% of cases, adenocarcinoma (AC) – 37.1% of cases and large cell carcinoma (LCC) – 3.2% of patients. [4]

It is difficult to obtain accurate epidemiological data on the occurrence of individual pathomorphological types of advanced LC in Poland. Up to date, no epidemiological studies have been conducted on a sufficiently large group of patients in advanced lung cancer to obtain reliable results. Statistics on pathomorphological diagnoses of lung cancer in material from bronchoscopy have not been conducted so far. In Poland, the main source of such data is the National Lung Cancer Registry which only contains details about patients undergoing surgery in earlier stages of the disease. Till today, there were 17 783 patients diagnosed and

operated in Polish thoracic surgery centers and registered in the National Lung Cancer Registry in the years 2014-2018. This group includes: 48.7% of patients with adenocarcinoma (AC), 40.8% of patients with squamous cell carcinoma (SCC), 6.45% of patients with large cell carcinoma (LCC), 2.1% of patients with adenosquamous cell carcinoma, 1.05% of patients with small cell lung cancer (SCLC) and 0.9% of patients with non-otherwise specified (NOS) non-small cell lung cancer (NSCLC). This material included a low percentage of patients with SCLC (usually an inoperable type of lung cancer) and patients with NSCLC-NOS (large surgical material is easier for pathomorphological examination which is a factor of reducing misdiagnosis). According to IASLC (International Association for the Study of Lung Cancer) recommendations, large cell carcinoma should be diagnosed only in the surgical materials extracted from the entire resected tumor. [5] Therefore, this type of cancer was recorded in surgical pathology in non-advanced NSCLC patients and almost absent in patients with advanced lung cancer diagnosed with tumor biopsy. [2]

Due to different locations of tumor types in the lungs or metastatic lymph nodes, varied approaches are required to cancer diagnosis. The peripheral location is characteristic for adenocarcinoma, while squamous and small cell carcinomas most often are located centrally. Bronchoscopy is an appropriate method for detecting LC and the endobronchial ultrasound-guided with transbronchial needle aspiration (EBUS-TBNA) procedure has an essential role in the investigation of lung cancer. If the tumor is centrally located and infiltrated the bronchus, the most optimal procedure seems to be the endobronchial biopsy using a brush or forceps. In contrast, adenocarcinoma frequently metastasizes to the mediastinal lymph nodes, which may be available on EBUS-TBNA or EUS-FNA procedures.

It is advisable to go along with the most easily available material, the collection of which will be associated with the lowest possible risk for the patient. In this connection, in everyday practice, the pathomorphological diagnosis is often achieved by metastatic lymph nodes. It is vital in diagnosing peripheral located tumors as adenocarcinoma.

Metastasis to the mediastinal lymph nodes is typical for each of types of lung cancer. We distinguish compartments of the mediastinal lymph nodes: superior mediastinal nodes (stations 2, 3 and 4), aortic nodes (stations 5 and 6), inferior mediastinal nodes (stations 7, 8, 9), hilar and interlobar lymph nodes (stations 10 and 11) and peripheral lymph nodes (station 12 for lobar nodes, station 13 for segmental nodes and station 14 for subsegmental nodes). EBUS-TBNA is most often used in diagnosis of superior mediastinal nodes, station 7 of inferior mediastinal nodes and stations 10, 11, 12 lymph nodes. EUS-FNA is preferred in diagnosis of superior mediastinal nodes and stations 7, 8 and 9 of inferior mediastinal nodes.

1
2
3 Moreover EUS-FNA is used to sampling subphrenic lymph nodes and metastases in liver and
4 left adrenal gland. Both methods – EBUS-TBNA and EUS-FNA are preferred for mediastinal
5 lymph nodes assessment for evaluation of N-stage in NSCLC patients. [6] These two methods
6
7 could be used in sampling visible tumors localized in central airways but also peripherally to
8
9 the main bronchi, i.e., in lobar or even segmental bronchi. These sampling principles were
10
11 also applied in our study in all the centers that participated in the study.
12

13 Lung cancer staging is initially assessed in imaging studies. Normal mediastinum
14 lymph nodes are defined below 10 mm in computed tomography (CT). Such a size of the
15 lymph nodes suggests the advancement of clinical stage N0. Currently, sampling for N0 nodes
16
17 is not recommended, while surgery is the primary treatment method for stage N0/N1 lung
18
19 cancer. However, everyday practice shows that it is worth collecting non-enlarged nodes for
20
21 pathomorphological examination, because cancer cells are often found in such nodes. [7,8]
22
23

24
25 The sensitivity of detecting lung cancer by different bronchoscopy methods varies
26
27 from 34% to 88% depending on the size and location of the tumor and preliminary diagnosis
28
29 of the patients. [9] Meta-analysis of 18 studies which included a total of 1,201 LC patients
30
31 was performed for assessment of sensitivity and specificity of ultrasound-guided fine needle
32
33 aspiration in mediastinal staging of lung cancer. Authors showed sensitivity of 83% (range
34
35 45-100%) and specificity of 97% (range 88-100%) of these methods. [10] In eight studies
36
37 limited to patients with enlarged mediastinal lymph nodes seen on CT, sensitivity was 90%
38
39 (95% CI: 84 to 94%) and specificity was 97% (95% CI: 95 to 98%). In patients without
40
41 enlarged mediastinal lymph nodes visible on CT, the overall sensitivity was 58% (95% CI:
42
43 39-75%). Therefore, the use of EBUS-TBNA increases the accuracy in the estimation of the
44
45 stage of lung cancer and may radically influence the further treatment of the patient and the
46
47 selection of the treatment method. Staging N2/N3 is a premise for the use of
48
49 radiochemotherapy and/or immunotherapy and allows the patient to be protected against the
50
51 burden of surgical procedure. EUS-FNA enables confirming the presence of distant
52
53 metastases, which has a decisive influence on therapeutic decisions. However, all false
54
55 negative results delay cancer diagnosis and force the repetition of diagnostic procedures
56
57 including surgery. Earlier detection of the lung cancer gives patients the chance for better
58
59 treatment. [11]
60

Aim

1
2
3 The objective of our study was to assess the yield of bronchoscopy in the diagnosis of
4 lung cancer. Especially, we devoted special attention to the possibility of diagnosis of
5 individual pathomorphological types of LC with various techniques use for collecting
6 materials during bronchoscopy.
7
8
9

10 11 **Material and methods**

12
13 In our observational cross-sectional study, we analyzed the results of
14 pathomorphological examination carried out on the material obtained by the 5279
15 bronchoscopies performed in 2016-2018. Those bronchoscopies were performed in three
16 Polish pulmonology departments. The study included 1892 women and 3387 men with
17 median age of 65 years.
18
19
20
21

22 **Patient and Public Involvement**

23
24 No patient involved. It was a retrospective study that relied fully on the documents gathered,
25 thus eliminating the need for collaboration between patients and researchers.
26

27
28 Various diseases of the respiratory system were indication for bronchoscopy: 3127
29 (59.2%) patients had suspicion of chest tumor in computed tomography, 882 (16.7%) patients
30 demonstrated hilar lymphadenopathy, 205 (3.9%) patients had suspicion of sarcoidosis and 20
31 (0.4%) patients had suspicion of pulmonary fibrosis. Other indications for bronchoscopy
32 occurred in 1045 (19.8%) patients (e.g. suspicion of tuberculosis, chronic cough, hemoptysis,
33 etc.). In patients with suspected cancer, samples of the tissue were taken through the
34 bronchoscopy and technique was chosen in compliance with tumor or metastatic lymph
35 node's location as it is described in the introduction. Forceps biopsies were performed using
36 Olympus BF-1T180 and Pentax EB-1970K bronchoscopes, EBUS-TBNA – using Olympus
37 BF-UC180F and Pentax EB-1970UK bronchoscopes (22-gauge needles), and EUS-FNA –
38 using Olympus GF-UCT180 endoscope. Premedication for bronchoscopy was under local or
39 general anesthesia, depending on the situation.
40
41
42
43
44
45
46
47

48
49 Samples underwent pathomorphological examination which included hematoxylin-
50 eosin (H&E) staining, mucicarmine staining and immunohistochemistry (IHC) examination
51 such as staining of TTF-1 (thyroid transcription factor 1) and p63/p40. Samples diagnosed
52 with non-squamous NSCLC were in-depth reported and underwent molecular testing for the
53 presence of EGFR mutation by real-time PCR technique (RT-PCR), ALK gene rearrangement
54 and PD-L1 expression by IHC. PD-L1 expression was also assessed in SCC patients. Large
55 cell carcinoma (LCC) of the lung according to The 2015 World Health Organization (WHO)
56 Classification of Tumors of the Lung, Pleura, Thymus and Heart cannot be diagnosed in small
57
58
59
60

specimens and aspiration biopsy materials. The diagnosis of LCC can only be made in the postoperative material. Therefore, there were no patients diagnosed with LCC in our study. Such patients were included in the group of patients diagnosed with NSCLC NOS. Chromogranin and synaptophysin was used in IHC examination of neuroendocrine tumors (small cell lung cancer or NSCLC NOS). All the centers participating in the study used these same procedures described above.

After receiving the diagnosis, we selected a population of patients with lung cancer and divided them to groups of patients with different cancer types (squamous cell lung cancer, adenocarcinoma, large cell carcinoma, not otherwise specified NSCLC, and small cell lung cancer). Then, we assessed the prevalence of different types of LC in the materials obtained with various bronchoscopic procedures.

Clinical and demographic factors were analyzed using the Pearson's Chi-square test. P-values below 0.05 were considered significant. The percentages reflect the relative number of all lung cancer patients diagnosed with a particular procedure. We only analyzed the results of the first-time bronchoscopy, that could be nondiagnostic. The evaluation of relative diagnostic yield (sensitivity) of different bronchoscopic procedures could not be done because, in our study, it was not possible to verify the final diagnosis of patient in the materials collected during the next bronchoscopy or another procedures (this applies mainly to patients with lung tumor or hilar lymphadenopathy). The following diagnostic procedures were carried out in various clinical centers throughout Poland. Therefore, we were unable to verify the diagnoses obtained later.

The protocol of the study was approved by the Committee of Ethics and Research at the Medical University of Lublin (KE-0254/5/2018).

Results

In 3565 (67.5%) patients, EBUS-TBNA and transesophageal EUS-FNA was performed and cytological material archived in a cytoblock was obtained. In 1346 (25.5%) patients, EBUS-TBNA (without EUS-FNA) was the only diagnostic procedure. In the remaining patients, EBUS-TBNA was supplemented by EUS-FNA. There were no patients in whom EUS-FNA would be the only diagnostic method. 1714 (32.5%) patients had non-ultrasound-guided bronchoscopy with the forceps biopsy of endobronchial lesions allowing to obtain a small histological specimen.

Lung cancer was confirmed in group of 1923 (36.42%) patients, including 1280 men and 643 women. Only reactive lymph nodes were found in 16.06% of the patients, sarcoidosis

1
2
3 was diagnosed in 4.13% of the patients, idiopathic pulmonary fibrosis – in 0.19% of the
4 patients, metastases to the lungs from other organs – in 2.39% of the patients. 40.81% of the
5 patients had no definitive diagnosis (Figure 1). Lung cancer was confirmed in 51% of patients
6 with suspected tumor in computed tomography. While, in the group of patients with hilar
7 lymphadenopathy, lung cancer was diagnosed in only 10.1% of cases.
8
9

10
11 Among patients with lung cancer, squamous cell carcinoma (32.07%) was most often
12 diagnosed, then adenocarcinoma (30.61%), small cell lung cancer (25.83%) and NSCLC-
13 NOS (11.49%) (Figure 2). SCLC and AC were significantly more frequent ($\chi^2 = 8.649$, $p =$
14 0.0033 and $\chi^2 = 21.128$, $p < 0.000005$, respectively) in women (29.97% and 37.42% of
15 women with lung cancer) than in men (23.75% and 27.19% of male patients with lung
16 cancer). Squamous cell carcinoma appeared significantly more often ($\chi^2 = 41.881$, $p <$
17 0.000001) among male (36.95%) than among female (22.36%) patients with lung cancer
18 (Figure 3). SCC was significantly more often ($\chi^2 = 4.17$, $p = 0.041$) diagnosed in the group of
19 patients older than 65 years than in younger patients. Other pathomorphological types of lung
20 cancer occurred with similar frequency in these two age groups.
21
22

23
24 Endobronchial biopsies significantly more often ($\chi^2 = 7.566$, $p = 0.0059$) provided
25 material for the diagnosis of lung cancer than the EBUS-TBNA and EUS-FNA procedures.
26 42.35% of endobronchial biopsies and 33.6% of TBNA and FNA provided material sufficient
27 to diagnose lung cancer. Fine needle biopsy of lymph nodes enabled the diagnosis of lung
28 cancer in 29.2% of cases, fine needle biopsy of lung tumor – in 66.6% of cases, and forceps
29 biopsy of bronchial mucosa lesions – in 48.2% of cases. These differences were statistically
30 significant.
31
32

33
34 Among patients with lung cancer, TBNA or FNA compared to endobronchial biopsies
35 were similarly effective ($\chi^2 = 0.656$, $p = 0.418$) in detecting SCLC (26.5% vs. 24.8%). On the
36 other hand, the diagnosis of AC and NSCLC-NOS was obtained significantly more frequently
37 ($\chi^2 = 20.394$, $p = 0.000006$ and $\chi^2 = 3.902$, $p = 0.0482$) in EBUS-TBNA and EUS-FNA
38 compared to endobronchial biopsies (34.3% vs. 24.52% and 12.6% vs. 9.6%, respectively).
39 SCC was significantly more often ($\chi^2 = 43.143$, $p < 0.000001$) diagnosed in material obtained
40 from forceps biopsy than in material from EBUS-TBNA and EUS-FNA (41.09% vs 26.62%)
41 which was directly related to the more frequent central location and bronchial infiltration of
42 this type of tumor. Computed tomography showed that in 79% of SCC patients the tumor was
43 centrally located in the large bronchi. The analysis of bronchoscopic images showed that
44 tumor deformed the bronchial mucosa or showed endobronchial growth in 67% of SCC
45 patients. (Figure 4). Table 1 shows the effectiveness of bronchoscopy in the diagnosis of
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 individual pathomorphological types of lung cancer depending on place of collecting the
4 material.
5
6
7

8 **Discussion**

9
10 Our study on the yield of EBUS-TBNA and forceps biopsy in obtaining material for
11 the diagnosis of various lung diseases is among the largest worldwide. The study points to
12 numerous problems arising from the use of these techniques in routine clinical practice. We
13 are aware of the many limitations of our study. First, we cannot determine the sensitivity and
14 specificity of our methods, because it was not possible to determine the final diagnosis in this
15 large group of patients (5 279 cases). In addition, we could not distinguish between material
16 collected by EBUS-TBNA and EUS-FNA. Thirdly, diagnosis of large cell carcinoma was not
17 possible in small specimens (LCC was probably qualified to the NSCLC-NOS group). A
18 limitation of our study was also the lack of detailed clinical and radiological characteristics of
19 all patients who underwent the bronchoscopy procedures.
20
21
22
23
24
25
26

27 However, we found that advanced small cell lung cancer may be more common in
28 Poland than previously thought. This tumor is characterized by rapid growth and metastases,
29 therefore, more often it could be diagnosed in advanced stages using bronchoscopic
30 techniques. EBUS-TBNA/EUS-FNA of lymph nodes and endobronchial biopsy had similar
31 efficiency in SCLC detection. Furthermore, the difference in the percentage of patients with
32 squamous cell carcinoma and adenocarcinoma diagnosed with endobronchial biopsies and
33 TBNA or FNA is noteworthy. In our study, most patients with adenocarcinoma were
34 diagnosed with EBUS-TBNA or EUS-FNA of lymph nodes, while patients with squamous
35 cell carcinoma were diagnosed more often based on examination of material from
36 endobronchial biopsy (forceps biopsy). Patients in cohort with squamous cell carcinoma were
37 more likely to have endobronchial disease accessible by forceps. Therefore we could not
38 ascertained that endobronchial biopsy is more effective for diagnosis of squamous cell lung
39 cancer as there was no comparison to EBUS-TBNA and EUS-FNA for those patients. Thus,
40 we point to the problem that effective bronchoscopic procedures depends on the location of
41 the primary tumor and the presence of metastases in the lymph nodes.
42
43
44
45
46
47
48
49
50
51
52

53 In addition to pathological diagnosis, molecular tests were also performed (*ALK* and
54 *ROS1* gene rearrangement, *EGFR* mutation, PD-L1 expression), which are necessary for
55 further qualification for treatment. These studies are made simultaneously from the same
56 cytoblock. The method of sampling during bronchoscopy may affect the diagnostic value of
57 the sample. Schmid-Bindert et al. performed prospective study in group of 106 patients with
58
59
60

1
2
3 NSCLC diagnosis. Authors used bronchoscopy methods to provide highest RNA yield for
4 multiple biomarker. They also compared diagnostic value of bronchoscopic samples in
5 molecular tests. By the way, the authors showed how often they detected different
6
7 pathomorphological types of lung cancer using various bronchoscopic methods. Small
8
9 biopsies were collected by three different methods: forceps biopsy (44.6%), EBUS-TBNA
10 (32.7%), and CT-guided core biopsy (22.8%). 38% of adenocarcinoma, 51% of squamous cell
11 carcinoma and 11% of NSCLC NOS were diagnosed using forceps biopsy. EBUS-TBNA
12 results were as follows: 45% of adenocarcinoma, 30% of squamous cell carcinoma and 24%
13 of NSCLC-NOS. The study showed the sufficient effectiveness of all three methods in the
14 diagnosis of lung cancer. However, it was indicated that the largest amount of genetic
15 material was collected using EBUS-TBNA and this method showed the highest diagnostic
16 value for molecular tests. [12]

17
18
19
20
21
22
23
24 Many authors emphasize that the diagnosis of NSCLC NOS is the most common in
25 the case of material obtained from EBUS-TBNA. Esterbrook et al. found that NSCLC-NOS
26 rate was 20.8% in EBUS-TBNA samples. Similar results were received by Navani et al. In
27 group of 774 patients with known or suspected lung cancer, 23% of patients had a final
28 diagnosis of NSCLC NOS. [13, 14] Our study confirmed the high percentage of NSCLC NOS
29 patients diagnosed with EBUS-TBNA procedures. Endobronchial biopsy was less likely to
30 provide a diagnosis of NOS NSCLC.

31
32
33
34
35
36 Chin et al. reported that EBUS-TBNA is the most sensitive diagnostic methods for
37 SCLC, because it allows to sample of specimens from mediastinal as well as submucosal
38 lesions. They also mentioned that the quality of specimens obtained by needle aspiration is
39 better than by forceps biopsies, which may contain crush artifacts. [15] In addition, other
40 studies noticed that the sensitivity of EBUS-TBNA for SCLC detection was higher than for
41 NSCLC diagnosis. [16, 17] Our findings confirmed above statements. The majority of SCLC
42 cases were diagnosed with EBUS-TBNA. Three SCLC patients were diagnosed from
43 metastatic lesions in the adrenal gland using transesophageal EUS-FNA.

44
45
46
47
48
49
50 Many authors raise the problem that forceps biopsy has low sensitivity in the diagnosis
51 of lung cancer. Forceps biopsy has a diagnostic yield ranging between 65-82%. In our
52 preliminary study conducted in 212 patients with lung cancer suspicion, we compared
53 sensitivity and accuracy of routine bronchoscopy with endobronchial biopsy, EBUS-TBNA,
54 and combination of EBUS-TBNA and EUS-FNA techniques. Sensitivity and accuracy of
55 endobronchial biopsy vs EBUS-TBNA vs combination of transbronchial biopsies were 43%
56 vs 44.3% vs 93.7% and 93.8% vs 94.7% and 94.8%, respectively. This demonstrates high
57
58
59
60

1
2
3 usefulness of the combination of EBUS-TBNA and EUS-FNA in the diagnosis of lung cancer
4 [18]. Verma et al. demonstrated sensitivity of EBUS-TBNA in cancer diagnosis of 91.4% in
5 small group of 37 patients with lesions located adjacent to the trachea or lesions located
6 adjacent to the main bronchi. [19] Tournoy et al. indicated that EBUS-TBNA has a sensitivity
7 of 82% and low negative predictive value (23%). [20] The similar results received Zhao et al.
8 for lesions located near the central airways. [21] Oki et al. showed that the combined
9 endoscopic method with EBUS-TBNA and EUS-FNA with a single bronchoscope gives
10 better results in staging of NSCLC than each technique alone. However, they mentioned that
11 significant number of patients had false-negative EBUS-TBNA and EUS-FNA results.
12 Moreover Oki et al. suggested that very important issue is bronchoscopists experience, which
13 may cause differences in the results. [22] On the other hand, Wallace et al. showed a EBUS-
14 TBNA sensitivity of only 69% in a group of 150 patients with lung cancer suspicion. [23]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Despite relatively low negative predictive value of EBUS-TBNA, there is an indication to perform other procedures (e.g., surgical procedures) for final diagnosis in a significant group of patients. In our study, 56.9% of patients who underwent bronchoscopy did not receive a definitive diagnosis of the diseases and they have been subjected to other diagnostic procedures or observations. We showed the results of all performed bronchoscopies and three different method of material collection (endobronchial biopsy and combination EBUS-TBNA and EUS-FNA). Moreover, unselected and heterogeneous patient population were recruited in three different hospitals that employ a total of 8 bronchoscopists. In most studies, the evaluation of the usefulness of EBUS-TBNA and EUS-FNA for detecting malignancy was conducted in selected patients with high clinical suspicion of the tumor. Small, preselected groups of patients with high risk of lung cancer could be the reason of the low negative predictive value of bronchoscopic procedures in these studies. Thus, these observations may not reflected the real clinical situation.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In studies where population was heterogenic regarding the disease (lung cancer, sarcoidosis, tuberculosis), EBUS-TBNA had diagnostic value only in 60-75% of patients. [24] Lange et al. showed diagnostic results of EBUS-TBNA in only 61.4% of unselected patients undergoing routine diagnostic procedures. [25] Fournier et al. examined 185 patients with extrathoracic malignancy and mediastinal lymphadenopathy in real life practice. Pathomorfological types of malignancy were successfully identified using EBUS-TBNA in only 93 patients (50.3%). The diagnostic sensitivity, specificity, negative predictive value, and positive predictive value were 68.4%, 100%, 53.3%, and 100%, respectively. [26] Murthi et al conducted research compare the accuracy of EBUS-TBNA to surgery in diagnosing hilar

1
2
3 and mediastinal pathologies. EBUS-TBNA for all pathologies had an accuracy of 81.2% and
4 sensitivity of 55.1%. [27]
5
6
7

8 **Conclusions**

9
10 Comparing all these data we could conclude that bronchoscopy is vital but not an ideal
11 technique in the routine diagnosis of respiratory diseases. Our study showed that 41%
12 bronchoscopy material was insufficient to perform reliable pathomorphological examination.
13 This mainly concerned patients with suspected lung tumor or lymphadenopathy. Especially,
14 here is a problem in the diagnosis of advanced lung tumors (mainly adenocarcinomas) if only
15 one procedure was performed during bronchoscopy. It is advisable to use several different
16 techniques of collecting specimens from both the tumor and the mediastinal lymph nodes
17 during bronchoscopy. The use of brush biopsy, forceps biopsy, bronchoaspirate analysis
18 EBUS-TBNA and EUS-FNA simultaneously or if desired was of the highest diagnostic value.
19 However, sometimes this fails and bronchoscopy must be repeated, or thoracic procedures
20 (e.g. mediastinoscopy or thoracoscopy) must be performed. We found that the EBUS-TBNA
21 value in daily clinical practice differed from that in clinical trials. Therefore, precise
22 estimation of the frequency of individual pathomorphological types of lung cancer based on
23 material obtained bronchoscopically is not possible. However, EBUS-TBNA play an essential
24 role in staging of invasive lung cancer. Therefore, its value in the diagnosis of lung cancer is
25 not limited to demonstrating the presence of cancer and its type, but above all to determining
26 the extent of the disease and qualification for appropriate treatment. It seems that the
27 incidence of lung cancer with a typical peripheral localization (adenocarcinoma) may be
28 underestimated in comparison to the incidence of lung cancer with a typical central
29 localization (squamous cell carcinoma, SCLC).
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Authorship contribution statement:**

47
48 Conception and design of the study: JB, MF, PK, JP. Administrative support: PK, JP, AP, JB,
49 AS, JS, MM, PK, RK, JM. Provision of study material or patients: JP, AP, JB, AS, JS, MM,
50 PK, RK, JM. Collection and assembly of data: JB, MF, PK, JP, AP, JB, AS, JS, MM, PK, RK.
51 Data analysis and interpretation: JB, MF, PK. Manuscript writing: JB, MF, PK. All authors
52 gave final approval of the published manuscript.
53
54
55
56
57

58 **Data Availability Statement:**

1
2
3 The data that support the findings of this study are available from the corresponding author
4 upon reasonable request.
5
6
7

8 Conflicts of Interest:

9
10 The authors declare no potential conflicts of interest.
11
12

13 Foundings:

14
15 This research did not receive any specific grant from funding agencies in the public,
16 commercial, or not-for-profit sectors.
17
18
19

20 Acknowledgements:

21
22 The authors would like to thank prof. Tadeusz Orłowski and prof. Maciej Krzakowski for
23 theirs helpful comments that improved the research and manuscript.
24
25
26

27 References

- 28
29 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. *CA Cancer J Clin.* 2017; 67: 7-30.
- 30
31 2. Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health
32 Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. *Thorac*
33 *Oncol.* 2015; 10: 1240-1242.
- 34
35 3. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN
36 estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA*
37 *Cancer J Clin.* 2018; 68: 394-424.
- 38
39 4. Houston KA, Henley SJ, Li J, et al. Patterns in lung cancer incidence rates and trends by
40 histologic type in the United States, 2004-2009. *Lung Cancer.* 2014; 86: 22-28.
- 41
42 5. Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S. The new IASLC/ATS/ERS
43 lung adenocarcinoma classification from a clinical perspective: current concepts and
44 future prospects. *J Thorac Dis.* 2014;6(Suppl 5): S526-S536
- 45
46 6. Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and oesophageal
47 endosonography for the diagnosis and staging of lung cancer. European Society of
48 Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European
49 Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). *Eur*
50 *Respir J.* 2015; 46: 40-60.
- 51
52 7. Gomez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M et al. Incidence of occult
53 mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative
54
55
56
57
58
59
60

- uptake of positron emission tomography/computer tomography scan. *Eur J Cardiothorac Surg.* 2010; 37: 1168-1174.
8. Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Problems in diagnosis and surgical management of clinical N1 non-small cell lung cancer. *Ann Thorac Surg.* 2005; 79: 1682-1685
 9. Rivera MP, Wahidi MM, Mehta AC. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2013; 143: 142-165.
 10. Micames CG, McCrory DC, Pavey DA, et al. Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and meta-analysis. *Chest.* 2007. 131: 539–548.
 11. Sutedja TG, Codrington H, Risse EK, et al. Autofluorescence bronchoscopy improves staging of radiographically occult lung cancer and has an impact on therapeutic strategy. *Chest.* 2001. 120: 1327-1332.
 12. Schmid-Bindert G, Wang Y, Jiang H, et al. EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods. *PLoS One.* 2013; 8: 77948.
 13. Navani N, Brown JM, Nankivell M, et al. Suitability of EBUS-TBNA specimens for subtyping and genotyping of NSCLC: a multi-centre study of 774 patients. *Am J Respir Crit Care Med.* 2012; 185: 1316-1322.
 14. Esterbrook G, Ananthhanam S, Plant PK. Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer. *Lung Cancer.* 2013; 80: 30-34.
 15. Chin R Jr, Cappellari JO, McCain TW, et al. Increasing use of bronchoscopic needle aspiration to diagnose small cell lung cancer. *Mayo Clin Proc.* 2000; 75: 796-801.
 16. Fernandez-Villar A, Botana M, Leiro V, et al. Validity and reliability of transbronchial needle aspiration for diagnosing mediastinal adenopathies. *BMC Pulm Med.* 2010; 10: 24.
 17. Sharafkhaneh A, Baaklini W, Gorin AB, et al. Yield of transbronchial needle aspiration in diagnosis of mediastinal lesions. *Chest.* 2003; 124: 2131-2135.
 18. Pasko E, Serafin-Bromblik J, Piekorz W, et al. Combined endobronchial and endoscopic ultrasound-guided needle aspiration performed by single ultrasound bronchoscopes routine videobronchoscopy for diagnosis of advanced lung cancer – a prospective study. *Eur Respir J.* 2016; 48: 2034.

19. Verma A, Jeon K, Koh WJ, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for the diagnosis of central lung parenchymal lesions. *Yonsei Med J.* 2013; 54: 672-678.
20. Tournoy KG, Rintoul RC, van Meerbeeck JP, et al. EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. *Lung Cancer.* 2009; 63: 45-49.
21. Zhao H, Xie Z, Zhou ZL, et al. Diagnostic value of endobronchial ultrasound-guided transbronchial needle aspiration in intrapulmonary lesions. *Chin Med J.* 2013; 126: 4312-4315.
22. Oki M, Saka H, Ando M, et al. Endoscopic ultrasound-guided fine needle aspiration and endobronchial ultrasound-guided transbronchial needle aspiration: Are two better than one in mediastinal staging of non-small cell lung cancer? *J Thorac Cardiovasc Surg.* 2014; 148: 1169-1177.
23. Wallace MB, Pascual JM, Raimondo M, et al. Minimally invasive endoscopic staging of suspected lung cancer. *JAMA.* 2008; 299: 540-546.
24. Madan K, Mohan A, Ayub II, et al. Initial experience with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) from a tuberculosis endemic population. *J Bronchol Interv Pulmonol.* 2014; 21: 208-214.
25. Lange T, Kunzendorf F, Pfeifer M, et al. Endobronchial ultrasound-guided transbronchial needle aspiration in routine care-plenty of benign results and follow-up tests. *Int J Clin Pract.* 2012; 66: 438-445.
26. Fournier C, Hermant C, Gounant V, et al. Diagnostic of mediastinal lymphadenopathy in extrathoracic cancer: a place for EBUS-TBNA in real life practice? *Respir Med Res.* 2019; 75: 1-4.
27. Murthi M, Donna E, Arias S, et al. Diagnostic Accuracy of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Real Life. *Front Med (Lausanne).* 2020; 7:118.

Table 1. The effectiveness of varies techniques during bronchoscopy in the diagnosis of individual pathomorphological types of lung cancer depending on place of collecting the material and nodal station.

Material	SCLC	Adenocarcinoma	Squamous cell	NOS	Total lung

			carcinoma		cancer
EBUS-TBNA/EUS-FNA of lymph nodes	250 (27.7%)	331 (36.7%)	209 (23.1%)	114 (12.5%)	904 (100%)
EBUS-TBNA/EUS-FNA of tumor	88 (24.7%)	94 (25.8%)	135 (37.2%)	44 (12.3%)	361 (100%)
EBUS-TBNA/EUS-FNA metastases to adrenal gland	3 (42.9%)	1 (14.3%)	2 (28.6%)	1 (14.3%)	7 (100%)
Forceps biopsy of tumor	156 (22%)	163 (25%)	270 (41.5%)	62 (9.5%)	651 (100%)

Figure 1. Results of pathomorphological examination carried out on material obtained from 5279 bronchoscopies (entire study population)

Figure 2. The incidence of individual pathomorphological types of LC in the entire study group of lung cancer patients

Figure 3. The incidence of individual pathomorphological types of LC according to the gender of patients with lung cancer

1
2
3 Figure 4. Percentage of patients with different types of lung cancer detected in materials
4 collected with different bronchoscopic techniques. Frequency of different types of lung cancer
5 was calculated in the whole group of patients undergoing a given bronchoscopic procedure
6 (100%), which resulted in the diagnosis of lung cancer
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Results of pathomorphological examination carried out on material obtained from 5279 bronchoscopies (entire study population)

108x60mm (300 x 300 DPI)




Figure 2. The incidence of individual pathomorphological types of LC in the entire study group of lung cancer patients

296x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. The incidence of individual pathomorphological types of LC according to the gender of patients with lung cancer

296x209mm (300 x 300 DPI)




Figure 4. Percentage of patients with different types of lung cancer detected in materials collected with different bronchoscopic techniques. Frequency of different types of lung cancer was calculated in the whole group of patients undergoing a given bronchoscopic procedure (100%), which resulted in the diagnosis of lung cancer

296x209mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	8

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
10				
11	Discussion			
12				
13	Key results	18	Summarise key results with reference to study objectives	9
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
15				
16	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11
17				
18				
19	Generalisability	21	Discuss the generalisability (external validity) of the study results	12
20				
21	Other information			
22	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
23				
24				

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Observational cross-sectional study of 5279 bronchoscopy results for the practical effectiveness of various biopsy techniques in the diagnosis of lung diseases with particular emphasis on lung cancer

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-043820.R2
Article Type:	Original research
Date Submitted by the Author:	17-May-2021
Complete List of Authors:	Błach, Justyna; Medical University of Lublin, Frąk, Małgorzata; Medical University of Lublin Krawczyk, Pawel; Medical University of Lublin Pankowski, Juliusz; Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska Pankowski, Adam; SilverSoft Buczowski, Jarosław; Medical University of Lublin Szlubowski, Artur; Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska Siwiec, Jan; Medical University of Lublin Krudyś, Piotr; Izer-Med Michnar, Marek; Medical University of Lublin Kieszko, Robert; Medical University of Lublin Milanowski, Janusz; Medical University of Lublin
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Oncology
Keywords:	Bronchoscopy < THORACIC MEDICINE, Respiratory tract tumours < ONCOLOGY, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Observational cross-sectional study of 5279 bronchoscopy results for the practical**
4 **effectiveness of various biopsy techniques in the diagnosis of lung diseases with**
5 **particular emphasis on lung cancer**
6
7
8
9

10 Justyna Błach^{1,2*}, Małgorzata Frąk^{1*}, Paweł Krawczyk¹, Juliusz Pankowski³, Adam
11 Pankowski⁴, Jarosław Buczkowski^{1,5}, Artur Szlubowski^{3,6}, Jan Siwiec¹, Piotr Krudys⁶, Marek
12 Michnar¹, Robert Kieszko¹, Janusz Milanowski¹
13
14

15 * authors equally contributing
16
17

18
19
20 1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin,
21 20-954 Lublin; Poland
22

23 2. Department of Clinical Immunology, Medical University of Lublin, 20-954 Lublin; Poland
24

25 3. Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska, 34-500 Zakopane, Poland
26

27 4. SilverSoft, Warszewska 64/1, 72-004 Pilchowo, Szczecin, Poland
28

29 5. Department of Lung Diseases and Intensive Care, Independent Public Provincial John of
30 God Hospital in Lublin, 20-400 Lublin, Poland
31

32 6. Izerski Pulmonology and Chemotherapy Center "IZER-MED", 58-580 Szklarska Poręba,
33 Poland
34
35

36
37
38
39
40
41 Short title: **The yield of bronchoscopy in the diagnosis of lung cancer**

42 **Corresponding author:**
43

44 Justyna Błach MD
45

46 Department of Pneumonology, Oncology and Allergology
47

48 Medical University of Lublin, Poland
49

50 Jaczewskiego 8, 20-954 Lublin, Poland
51

52 tel. +48 81 724 42 93
53

54 e-mail: justynablach91@gmail.com
55
56
57
58
59
60

Abstract

Introduction

Bronchoscopy is the main method in the diagnosis of various lung diseases. Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is the most modern bronchoscopic technique useful in diagnosis and staging of lung cancer.

Objectives

The aim of the study was to assess the yield of bronchoscopy in patients with suspected various respiratory diseases including lung cancer. In particular, we examined the efficiency of different biopsy techniques in the diagnosis of lung cancer in correlation with its localization and pathomorphological type.

Patients and Methods

The results of pathomorphological examinations from 5279 bronchoscopies performed in 2016-2018 were analyzed. The material was collected with endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA), endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and endobronchial forceps biopsy. Clinical and demographic factors were analyzed using the Fisher χ^2 test.

Results

5279 patients were diagnosed due to various respiratory symptoms. Lung cancer was confirmed in 36.42% of patients. 40.81% of patients had no definitive pathomorphological diagnosis. Among patients with lung cancer, the most frequent diagnosis was non-small cell lung cancer: squamous cell lung cancer (SCC) - 32.07% and adenocarcinoma (AC) - 30.61%, then small cell lung cancer (SCLC) - 25.83% and not otherwise specified non-small cell lung cancer (NSCLC NOS) - 11.49%. Diagnosis of SCC was obtained significantly more often ($\chi^2=43.143$, $p<0.000001$) by forceps biopsy (41.09%) than by EBUS-TBNA/EUS-FNA (26.62%). On the contrary, diagnosis of AC or NSCLC NOS was significantly more often ($\chi^2=20.394$, $p<0.000007$ and $\chi^2=3.902$, $p<0.05$, respectively) observed in EBUS-TBNA/EUS-FNA (34.31% and 12.6%) than in endobronchial biopsies (24.52% and 9.64%).

Conclusions

The use of bronchoscopy in the diagnosis of various lung diseases is vital but also has many limitations. Effectiveness of EBUS-TBNA and endobronchial forceps biopsy in diagnosis of lung cancer is strongly affected by tumor localization and type of cancer.

Key words: lung cancer; bronchoscopy; endobronchial biopsy; EBUS-TBNA; EUS-FNA

Article summary

Strengths and limitations of this study

1. 5 279 patients were enrolled to the study group which makes it one of the largest studies in the world with assessment of bronchoscopy effectiveness in routine clinical practice.
2. We analyzed bronchoscopies performed in 2016-2018 in a few polish medical centers across the country, in a diversified population which ensures a high level of generalisability.
3. The study is an important contribution to the epidemiological data of advanced lung cancer in Poland.
4. Bronchoscopies were performed by 8 different bronchoscopists. This fact may cause human-dependent variation in results.
5. Results of pathomorphological assessment of the material obtained during single bronchoscopy was analyzed. Patients without diagnosed disease in the bronchoscopic material underwent further diagnostics using other methods or in other centers. Therefore, we were unable to report a definitive diagnosis in patients with inconclusive results of diagnostic procedures.

Introduction

Epidemiological analyses indicate that lung cancer (LC) is the most common cause of cancer-related deaths. It is usually diagnosed in an unresectable, advanced stage. [1, 2] Lung cancer is the most common cancer in men and the third most common in women. In 2018, there were more than 2 million new cases of lung cancer worldwide. [3]

In the United States from 2004 to 2009, a total of 1,096,276 lung cancer cases were diagnosed and reported. This American study investigated the histologic type of lung cancer and demographic characteristics of the patients. The incidence of individual types of LC was as follows: small cell lung cancer (SCLC) – 14.9%, squamous cell carcinoma (SCC) – 21.9%, adenocarcinoma (AC) – 37.1% and large cell carcinoma (LCC) – 3.2% of cases. [4]

It is difficult to obtain accurate epidemiological data on the occurrence of individual pathomorphological types of advanced LC in Poland. Up to date, no epidemiological studies have been conducted on a sufficiently large group of patients with advanced lung cancer to obtain reliable results. Statistics on pathomorphological diagnoses of lung cancer in material from bronchoscopy have not been conducted so far. In Poland, the main source of such data is the National Lung Cancer Registry which only contains details about patients undergoing surgery in earlier stages of the disease. There were 17,783 patients diagnosed and operated in Polish thoracic surgery centers and registered in the National Lung Cancer Registry in the years

1
2
3 2014-2018. This group includes: 48.7% of patients with AC, 40.8% of patients with SCC,
4 6.45% of patients with LCC, 2.1% of patients with adenosquamous cell carcinoma, 1.05% of
5 patients with SCLC and 0.9% of patients with non-otherwise specified (NOS) non-small cell
6 lung cancer (NSCLC). This material included low percentage of patients with SCLC (usually
7 an inoperable type of lung cancer) and patients with NSCLC-NOS (large surgical material is
8 easier for pathomorphological examination which is a factor of reducing misdiagnosis).
9 According to IASLC (International Association for the Study of Lung Cancer)
10 recommendations, large cell carcinoma should be diagnosed only in surgical materials extracted
11 from the entire resected tumor. [5] Therefore, this type of cancer was recorded in surgical
12 pathology in non-advanced NSCLC patients and almost absent in patients with advanced lung
13 cancer diagnosed with tumor biopsy. [2]

14
15
16
17
18
19
20
21
22 Due to different locations of tumor types in the lungs or metastatic lymph nodes, varied
23 approaches are required to cancer diagnosis. The peripheral location is characteristic for AC,
24 while squamous and small cell carcinomas most often are located centrally. Bronchoscopy is
25 an appropriate method for detecting LC and the endobronchial ultrasound-guided with
26 transbronchial needle aspiration (EBUS-TBNA) procedure has an essential role in the
27 investigation of lung cancer. If the tumor is centrally located and infiltrated the bronchus, the
28 most optimal procedure seems to be the endobronchial biopsy using a brush or forceps. In
29 contrast, adenocarcinoma frequently metastasizes to the mediastinal lymph nodes, which may
30 be available on EBUS-TBNA or EUS-FNA procedures.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Metastasis to mediastinal lymph nodes is typical for each of types of lung cancer. We
distinguish compartments of the mediastinal lymph nodes: superior mediastinal nodes (stations
2, 3 and 4), aortic nodes (stations 5 and 6), inferior mediastinal nodes (stations 7, 8, 9), hilar
and interlobar lymph nodes (stations 10 and 11) and peripheral lymph nodes (station 12 for
lobar nodes, station 13 for segmental nodes and station 14 for subsegmental nodes). EBUS-
TBNA is most often used in diagnosis of superior mediastinal nodes, station 7 of inferior
mediastinal nodes and stations 10, 11, 12 lymph nodes. EUS-FNA is preferred in diagnosis of
superior mediastinal nodes and stations 7, 8 and 9 of inferior mediastinal nodes. Moreover EUS-
FNA is used for sampling subphrenic lymph nodes and metastases in liver and left adrenal
gland. Both methods – EBUS-TBNA and EUS-FNA are preferred for mediastinal lymph nodes
assessment for evaluation of N-stage in NSCLC patients. [6] These two methods could be used
in sampling visible tumors localized in central airways but also peripherally to the main bronchi,
i.e. in lobar or even segmental bronchi.

1
2
3 Lung cancer staging is initially assessed through imaging studies. Normal mediastinum
4 lymph nodes are defined below 10 mm in computed tomography (CT). Such a size of these
5 lymph nodes suggests the N0 clinical stage. Currently, sampling for N0 nodes is not
6 recommended, while surgery is the primary treatment method for N0/N1 stage of lung cancer.
7 However, everyday practice shows that it is worth collecting non-enlarged nodes for
8 pathomorphological examination, because cancer cells are often found in such nodes. [7,8]
9

10
11
12 The sensitivity of detecting lung cancer using different bronchoscopy methods varies
13 from 34% to 88% depending on the size and location of the tumor and preliminary diagnosis of
14 the patients. [9] Meta-analysis of 18 studies which included a total of 1,201 LC patients was
15 performed for assessment of sensitivity and specificity of ultrasound-guided fine needle
16 aspiration in mediastinal staging of lung cancer. Authors showed sensitivity of 83% (range 45-
17 100%) and specificity of 97% (range 88-100%) of these methods. [10] In eight studies limited
18 to patients with enlarged mediastinal lymph nodes seen on CT, sensitivity was 90% (95% CI:
19 84 to 94%) and specificity was 97% (95% CI: 95 to 98%). In patients without enlarged
20 mediastinal lymph nodes visible on CT, the overall sensitivity was 58% (95% CI: 39-75%).
21 Therefore, the use of EBUS-TBNA increases the accuracy in the estimation of the stage of lung
22 cancer and may radically influence the further treatment of the patient and the selection of the
23 treatment methods. EUS-FNA enables confirming the presence of distant metastases, which has
24 a decisive impact on therapeutic decisions. However, all false negative results delay cancer
25 diagnosis and force the repetition of diagnostic procedures including surgery. Earlier detection
26 of lung cancer gives patients the chance for better treatment. [11]
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Aim**

42
43
44 The objective of our study was a descriptive analysis of lung diseases diagnoses,
45 especially lung cancer, established by various bronchoscopic procedures. We devoted special
46 attention to the possibility of diagnosis of individual pathomorphological types of LC with
47 various techniques used for collecting materials during bronchoscopy.
48
49
50
51
52
53
54

55 **Material and methods**

56
57 In our observational cross-sectional study, we analyzed the results of
58 pathomorphological examination carried out on the material obtained during 5279
59 bronchoscopies performed in 2016-2018. Those bronchoscopies were performed in three Polish
60

1
2
3 pulmonology departments. The study included 1892 women and 3387 men, with median age
4 of 65 years.

5
6 The study was retrospective and relied fully on the analysis of documents gathered, thus
7 eliminating the need for collaboration between patients and researchers. No patients were
8 enrolled specifically to carry out this study.

9
10
11 Various diseases of the respiratory system were indication for bronchoscopy: 3127
12 (59.2%) patients had suspicion of chest tumor in computed tomography, 882 (16.7%) patients
13 demonstrated hilar lymphadenopathy, 205 (3.9%) patients had suspicion of sarcoidosis and 20
14 (0.4%) patients had suspicion of pulmonary fibrosis. Other indications for bronchoscopy
15 occurred in 1045 (19.8%) patients (e.g. suspicion of tuberculosis, chronic cough, hemoptysis,
16 etc.). In patients with suspected cancer, samples of the tissue were acquired through
17 bronchoscopy and the technique was chosen in compliance with tumor or metastatic lymph
18 node's location as it is described in the introduction. Forceps biopsies were performed using
19 Olympus BF-1T180 and Pentax EB-1970K bronchoscopes, EBUS-TBNA – using Olympus
20 BF-UC180F and Pentax EB-1970UK bronchoscopes (22-gauge needles), and EUS-FNA –
21 using Olympus GF-UCT180 endoscope. Premedication for bronchoscopy was under local or
22 general anesthesia, depending on the situation.

23
24
25 Samples underwent pathomorphological examination which included hematoxylin-
26 eosin (H&E) staining, mucicarmine staining and immunohistochemistry (IHC) examination,
27 such as staining of TTF-1 (thyroid transcription factor 1) and p63/p40. Samples diagnosed with
28 non-squamous NSCLC were in-depth reported and underwent molecular testing for the
29 presence of *EGFR* gene mutation by real-time PCR technique (RT-PCR), *ALK* gene
30 rearrangement and PD-L1 expression by IHC. PD-L1 expression was also assessed in SCC
31 patients. Large cell carcinoma (LCC) of the lung according to the 2015 World Health
32 Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart cannot
33 be diagnosed in small specimens and aspiration biopsy materials. The diagnosis of LCC can
34 only be made in the postoperative material. Therefore, there were no patients diagnosed with
35 LCC in our study. Such patients were included in the group of patients diagnosed with NSCLC
36 NOS. Chromogranin and synaptophysin was used in IHC examination of neuroendocrine
37 tumors (small cell lung cancer or NSCLC NOS). All the centers participating in the study used
38 these same procedures described above.

39
40
41 After receiving the diagnosis, we selected a population of patients with lung cancer and
42 divided them into groups of patients with different cancer types detectable with bronchoscopic
43 procedure (squamous cell lung cancer, adenocarcinoma, large cell carcinoma, not otherwise
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 specified NSCLC, and small cell lung cancer). Then, we assessed the prevalence of different
4 types of LC in the materials obtained with various bronchoscopic procedures.
5

6 Clinical and demographic factors were analyzed using the Pearson's Chi-square test. P-
7 values below 0.05 were considered significant. The percentages reflect the relative number of
8 all lung cancer patients diagnosed with a particular procedure. We only analyzed the results of
9 the first-time bronchoscopy, that could be nondiagnostic. The evaluation of relative diagnostic
10 yield (sensitivity) of different bronchoscopic procedures could not be done because, in our
11 study, it was not possible to verify the final diagnosis of patients in the materials collected
12 during the next bronchoscopy or another procedures (this applies mainly to patients with lung
13 tumor or hilar lymphadenopathy). The following diagnostic procedures were carried out in
14 various clinical centers throughout Poland. Therefore, we were unable to verify the diagnoses
15 obtained later.
16
17
18
19
20
21
22
23

24 The protocol of the study was approved by the Committee of Ethics and Research at the
25 Medical University of Lublin (KE-0254/5/2018).
26
27
28

29 Results

30 In 3565 (67.5%) patients, EBUS-TBNA and transesophageal EUS-FNA was performed
31 and cytological material was archived in a cellblock. In 1346 (25.5%) patients, EBUS-TBNA
32 (without EUS-FNA) was the only diagnostic procedure. In the remaining patients, EBUS-
33 TBNA was supplemented by EUS-FNA. There were no patients in whom EUS-FNA would be
34 the only diagnostic method. 1714 (32.5%) patients had non-ultrasound-guided bronchoscopy
35 with the forceps biopsy of endobronchial lesions allowing to obtain a small histological
36 specimen.
37
38
39
40
41
42

43 Lung cancer was confirmed in a group of 1923 (36.42%) patients, including 1280 men
44 and 643 women. Reactive lymph nodes were found in 16.06% of the patients, sarcoidosis was
45 diagnosed in 4.13%, idiopathic pulmonary fibrosis – in 0.19%, metastases to the lungs from
46 other organs – in 2.39% of the patients. 40.81% of the patients had no definitive diagnosis
47 (Figure 1). Lung cancer was confirmed in 51% of patients with suspected tumor in computed
48 tomography. While, in the group of patients with hilar lymphadenopathy, lung cancer was
49 diagnosed in only 10.1% of cases.
50
51
52
53

54 Among those with lung cancer, squamous cell carcinoma (32.07%) was most often
55 diagnosed, then adenocarcinoma (30.61%), small cell lung cancer (25.83%) and NSCLC-NOS
56 (11.49%) (Figure 2). SCLC and AC were significantly more frequent ($\chi^2 = 8.649$, $p = 0.0033$
57 and $\chi^2 = 21.128$, $p < 0.000005$, respectively) in women (29.97% and 37.42% of women with
58
59
60

lung cancer) than in men (23.75% and 27.19% of male patients with lung cancer). Squamous cell carcinoma appeared significantly more often ($\chi^2 = 41.881$, $p < 0.000001$) among male (36.95%) than among female (22.36%) patients with lung cancer (Figure 3). SCC was significantly more often ($\chi^2 = 4.17$, $p = 0.041$) diagnosed in the group of patients older than 65 years than in younger patients. Other pathomorphological types of lung cancer occurred with similar frequency in these two age groups.

Endobronchial biopsies significantly more often ($\chi^2 = 7.566$, $p = 0.0059$) provided material for the diagnosis of lung cancer than the EBUS-TBNA and EUS-FNA procedures. 42.35% of endobronchial biopsies and 33.6% of TBNA and FNA provided material sufficient to diagnose lung cancer. Fine needle biopsy of lymph nodes enabled the diagnosis of lung cancer in 29.2% of cases, fine needle biopsy of lung tumor – in 66.6% of cases, and forceps biopsy of bronchial mucosa lesions – in 48.2% of cases. These differences were statistically significant.

Among patients with lung cancer, TBNA or FNA compared to endobronchial biopsies gave a similar result ($\chi^2 = 0.656$, $p = 0.418$) in detection of SCLC (26.5% vs. 24.8%). On the other hand, the diagnosis of AC and NSCLC-NOS was obtained significantly more frequently ($\chi^2 = 20.394$, $p = 0.000006$ and $\chi^2 = 3.902$, $p = 0.0482$) in EBUS-TBNA and EUS-FNA compared to endobronchial biopsies (34.3% vs. 24.52% and 12.6% vs. 9.6%, respectively). SCC, among other lung cancer types detected by bronchoscopy, was diagnosed in 41.77% in materials obtained by forceps biopsy and only in 26.62% in materials with EBUS-TBNA or EUS-FNA ($\chi^2 = 43.143$, $p < 0.000001$), which was directly related to the more frequent central location and bronchial infiltration of this type of tumor. Computed tomography showed that in 79% of SCC patients the tumor was centrally located in the large bronchi. The analysis of bronchoscopic images showed that tumor deformed the bronchial mucosa or showed endobronchial growth in 67% of SCC patients. (Figure 4). Table 1 shows the results of bronchoscopy procedures in the diagnosis of individual pathomorphological types of lung cancer depending on place of collecting the material.

Discussion

Our study on the results of EBUS-TBNA/EUS-FNA and forceps biopsy in obtaining materials for the diagnosis of various lung diseases is among the largest worldwide. The study points to numerous problems arising from the use of these techniques in routine clinical practice. We are aware of the many limitations of our study. First, we cannot determine the sensitivity and specificity of our methods, because it was not possible to determine the final

1
2
3 diagnosis in such a large group of patients (5 279 cases). In addition, we could not distinguish
4 between material collected by EBUS-TBNA and EUS-FNA. We do not know how many lung
5 cancer patients were diagnosed only in the material from EBUS-TBNA or only in the material
6 from EUS-FNA, or in both types of these materials. We also do not know the number of biopsies
7 performed during one bronchoscopy. This data is missing from the results of the
8 pathomorphological examination that we analyzed. Thirdly, diagnosis of large cell carcinoma
9 was not possible in small specimens (LCC was probably qualified to the NSCLC-NOS group).
10 A limitation of our study was also the lack of detailed clinical and radiological characteristics
11 of all patients who underwent bronchoscopy procedures.
12

13
14
15 However, we found that advanced small cell lung cancer may be more common in
16 Poland than previously thought. This tumor is characterized by rapid growth and metastases,
17 therefore, more often it could be diagnosed in advanced stages using bronchoscopic techniques.
18 SCLC diagnosis in EBUS-TBNA/EUS-FNA of lymph nodes and endobronchial biopsy occurs
19 at the same frequency. Furthermore, the difference in the percentage of patients with squamous
20 cell carcinoma and adenocarcinoma diagnosed with endobronchial biopsies and TBNA or FNA
21 is noteworthy. In our study, most patients with adenocarcinoma were diagnosed with EBUS-
22 TBNA or EUS-FNA of lymph nodes, while patients with squamous cell carcinoma were
23 diagnosed more often based on examination of material from endobronchial biopsy (forceps
24 biopsy). Patients in cohort with squamous cell carcinoma were more likely to have
25 endobronchial disease accessible by forceps. Therefore we could not ascertain that
26 endobronchial biopsy is more effective for diagnosis of squamous cell lung cancer as there was
27 no comparison to EBUS-TBNA and EUS-FNA for those patients. Thus, we point to the problem
28 that results of bronchoscopic procedures depends on the location of the primary tumor and the
29 presence of metastases in the lymph nodes.
30

31
32 Schmid-Bindert et al. showed how often they detected different pathomorphological
33 types of lung cancer using various bronchoscopic methods. Small biopsies were collected by
34 three different methods: forceps biopsy (44.6%), EBUS-TBNA (32.7%), and CT-guided core
35 biopsy (22.8%). 38% of adenocarcinoma, 51% of squamous cell carcinoma and 11% of NSCLC
36 NOS were diagnosed using forceps biopsy. EBUS-TBNA results were as follows: 45% of
37 adenocarcinoma, 30% of squamous cell carcinoma and 24% of NSCLC NOS. [12]
38

39
40 Many authors emphasize that the diagnosis of NSCLC NOS is the most common in the
41 case of material obtained from EBUS-TBNA. Esterbrook et al. found that NSCLC-NOS rate
42 was 20.8% in EBUS-TBNA samples. Similar results were achieved by Navani et al. In group
43 of 774 patients with known or suspected lung cancer, 23% of patients had a final diagnosis of
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 NSCLC NOS. [13, 14] Our study confirmed the high percentage of NSCLC NOS patients
4 diagnosed with EBUS-TBNA procedures. Endobronchial biopsy was less likely to provide a
5 diagnosis of NSCLC NOS.
6
7

8 Chin et al. reported that EBUS-TBNA is the most sensitive diagnostic method for SCLC
9 detection, because it allows to sample specimens from mediastinal as well as submucosal
10 lesions. They also mentioned that the quality of specimens obtained by needle aspiration is
11 better than by forceps biopsies, which may contain crushed artifacts. [15] In addition, other
12 studies noticed that the sensitivity of EBUS-TBNA for SCLC detection was higher than for
13 NSCLC diagnosis. [16, 17] Our findings confirmed the above statements. The majority of
14 SCLC cases were diagnosed with EBUS-TBNA. Three SCLC patients were diagnosed from
15 metastatic lesions in the adrenal gland using transesophageal EUS-FNA.
16
17

18 Many authors raise the problem that forceps biopsy has low sensitivity in the diagnosis
19 of lung cancer. Forceps biopsy has a diagnostic yield ranging between 65-82%. In preliminary
20 study by Pasko et al. conducted in 212 patients with lung cancer suspicion, authors compared
21 sensitivity and accuracy of routine bronchoscopy techniques: endobronchial biopsy, EBUS-
22 TBNA, and combination of EBUS-TBNA and EUS-FNA. Sensitivity and accuracy of
23 endobronchial biopsy vs EBUS-TBNA vs combination of transbronchial biopsies were 43% vs
24 44.3% vs 93.7% and 93.8% vs 94.7% and 94.8%, respectively. This demonstrates high
25 usefulness of the combination of EBUS-TBNA and EUS-FNA in the diagnosis of lung cancer
26 [18]. Verma et al. demonstrated sensitivity of EBUS-TBNA in cancer diagnosis of 91.4% in
27 small group of 37 patients with lesions located adjacent to the trachea or lesions located adjacent
28 to the main bronchi. [19] Tournoy et al. indicated that EBUS-TBNA has a sensitivity of 82%
29 and low negative predictive value (23%). [20] The similar results were received by Zhao et al.
30 for lesions located near the central airways. [21] Oki et al. showed that the combined endoscopic
31 method with EBUS-TBNA and EUS-FNA with a single bronchoscope gives better results in
32 staging of NSCLC, than each technique alone. However, they mentioned that significant
33 number of patients had false-negative EBUS-TBNA and EUS-FNA results. Moreover Oki et
34 al. suggested that very important issue is bronchoscopists experience, which may cause
35 differences in the results. [22] On the other hand, Wallace et al. showed a EBUS-TBNA
36 sensitivity of only 69% in a group of 150 patients with lung cancer suspicion. [23]
37
38

39 Despite relatively low negative predictive value of EBUS-TBNA, there is an indication
40 to perform other procedures (e.g., surgical procedures) for final diagnosis in a significant group
41 of patients. In our study, 56.9% of patients who underwent bronchoscopy did not receive a
42 definitive diagnosis of the diseases and they have been subjected to other diagnostic procedures
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 or observations. We showed the results of all performed bronchoscopies and three different
4 methods of material collection (endobronchial biopsy and combination EBUS-TBNA and EUS-
5 FNA). Moreover, unselected and heterogeneous patients were recruited in three different
6 hospitals that employ a total of 8 bronchoscopists. In most studies, the evaluation of the
7 usefulness of EBUS-TBNA and EUS-FNA for detecting malignancy was conducted in selected
8 patients with high clinical suspicion of the tumor. Small, preselected groups of patients with
9 high risk of lung cancer could be the reason of the low negative predictive value of
10 bronchoscopic procedures in these studies. Thus, these observations may not reflected the real
11 clinical situation.
12
13
14
15
16
17
18

19 In studies where population was heterogenic regarding the disease (lung cancer,
20 sarcoidosis, tuberculosis), EBUS-TBNA had diagnostic value only in 60-75% of patients. [24]
21 Lange et al. showed diagnostic results of EBUS-TBNA in only 61.4% of unselected patients
22 undergoing routine diagnostic procedures. [25] Fournier et al. examined 185 patients with
23 extrathoracic malignancy and mediastinal lymphadenopathy in real life practice.
24 Pathomorphological types of malignancy were successfully identified using EBUS-TBNA in
25 only 93 patients (50.3%). The diagnostic sensitivity, specificity, negative predictive value, and
26 positive predictive value were 68.4%, 100%, 53.3%, and 100%, respectively. [26] Murthi et al
27 conducted research comparing the accuracy of EBUS-TBNA to surgery in diagnosis of hilar
28 and mediastinal pathologies. EBUS-TBNA for all pathologies had an accuracy of 81.2% and
29 sensitivity of 55.1%. [27]
30
31
32
33
34
35
36
37
38

39 **Conclusions**

40
41 Comparing all these data, we could conclude that bronchoscopy is vital but not an ideal
42 technique in the routine diagnosis of respiratory diseases. Our study showed that 41% of
43 bronchoscopy materials were insufficient to perform reliable pathomorphological examination.
44 This mainly concerned patients with suspected lung tumor or lymphadenopathy. The use of
45 brush biopsy, forceps biopsy, bronchoaspirate analysis EBUS-TBNA and EUS-FNA
46 simultaneously, if desired, was of the highest diagnostic value. However, sometimes this fails
47 and bronchoscopy must be repeated, or thoracic procedures (e.g. mediastinoscopy or
48 thoracoscopy) must be performed. We found that the EBUS-TBNA value in daily clinical
49 practice differed from that in clinical trials. Therefore, precise estimation of the frequency of
50 individual pathomorphological types of lung cancer, based on material obtained
51 bronchoscopically, is not possible. However, EBUS-TBNA plays an essential role in staging of
52 invasive lung cancer. Therefore, its value in the diagnosis of lung cancer is not limited to
53
54
55
56
57
58
59
60

1
2
3 demonstrating the presence of cancer type, but, above all, to determining the extent of the
4 disease and qualification for appropriate treatment. It seems that the incidence of lung cancer
5 with a typical peripheral localization (adenocarcinoma) may be underestimated in comparison
6 to the incidence of lung cancer with a typical central localization (squamous cell carcinoma,
7 SCLC), when bronchoscopy is used as the primary diagnostic method.
8
9
10
11
12

13 Authorship contribution statement:

14 Conception and design of the study: JB, MF, PK, JP. Administrative support: PK, JP, AP, JB,
15 AS, JS, MM, PK, RK, JM. Provision of study material or patients: JP, AP, JB, AS, JS, MM,
16 PK, RK, JM. Collection and assembly of data: JB, MF, PK, JP, AP, JB, AS, JS, MM, PK, RK.
17 Data analysis and interpretation: JB, MF, PK. Manuscript writing: JB, MF, PK. All authors
18 gave final approval of the published manuscript.
19
20
21
22
23
24

25 Data Availability Statement:

26 The data that supports the findings of this study are available from the corresponding author
27 upon reasonable request.
28
29
30
31

32 Conflicts of Interest:

33 The authors declare no potential conflicts of interest.
34
35
36
37

38 Fundings:

39 This research did not receive any specific grant from funding agencies in the public,
40 commercial, or not-for-profit sectors.
41
42
43
44
45
46
47

48 Acknowledgements:

49 The authors would like to thank prof. Tadeusz Orłowski and prof. Maciej Krzakowski for
50 their helpful comments that improved the research and manuscript.
51
52
53
54

55 References

- 56 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. CA Cancer J Clin. 2017; 67: 7-30.
57
58
59
60

- 1
2
3 2. Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health
4 Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. *Thorac*
5 *Oncol.* 2015; 10: 1240-1242.
- 6
7
8 3. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN
9 estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA*
10 *Cancer J Clin.* 2018; 68: 394-424.
- 11
12 4. Houston KA, Henley SJ, Li J, et al. Patterns in lung cancer incidence rates and trends by
13 histologic type in the United States, 2004-2009. *Lung Cancer.* 2014; 86: 22-28.
- 14
15 5. Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S. The new IASLC/ATS/ERS
16 lung adenocarcinoma classification from a clinical perspective: current concepts and
17 future prospects. *J Thorac Dis.* 2014;6(Suppl 5): S526-S536
- 18
19 6. Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and oesophageal
20 endosonography for the diagnosis and staging of lung cancer. European Society of
21 Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European
22 Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). *Eur*
23 *Respir J.* 2015; 46: 40-60.
- 24
25 7. Gomez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M et al. Incidence of occult
26 mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative
27 uptake of positron emission tomography/computer tomography scan. *Eur J Cardiothorac*
28 *Surg.* 2010; 37: 1168-1174.
- 29
30 8. Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Problems in diagnosis and surgical
31 management of clinical N1 non-small cell lung cancer. *Ann Thorac Surg.* 2005; 79: 1682-
32 1685
- 33
34 9. Rivera MP, Wahidi MM, Mehta AC. Establishing the diagnosis of lung cancer: Diagnosis
35 and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-
36 based clinical practice guidelines. *Chest.* 2013; 143: 142-165.
- 37
38 10. Micames CG, McCrory DC, Pavey DA, et al. Endoscopic ultrasound-guided fine-needle
39 aspiration for non-small cell lung cancer staging: A systematic review and meta-analysis.
40 *Chest.* 2007. 131: 539-548.
- 41
42 11. Sutedja TG, Codrington H, Risse EK, et al. Autofluorescence bronchoscopy improves
43 staging of radiographically occult lung cancer and has an impact on therapeutic strategy.
44 *Chest.* 2001. 120: 1327-1332.
- 45
46 12. Schmid-Bindert G, Wang Y, Jiang H, et al. EBUS-TBNA provides highest RNA yield for
47 multiple biomarker testing from routinely obtained small biopsies in non-small cell lung
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 cancer patients - a comparative study of three different minimal invasive sampling
4 methods. PLoS One. 2013; 8: 77948.
5
6
7 13. Navani N, Brown JM, Nankivell M, et al. Suitability of EBUS-TBNA specimens for
8 subtyping and genotyping of NSCLC: a multi-centre study of 774 patients. Am J Respir
9 Crit Care Med. 2012; 185: 1316-1322.
10
11
12 14. Esterbrook G, Anathhanam S, Plant PK. Adequacy of endobronchial ultrasound
13 transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer.
14 Lung Cancer. 2013; 80: 30-34.
15
16
17 15. Chin R Jr, Cappellari JO, McCain TW, et al. Increasing use of bronchoscopic needle
18 aspiration to diagnose small cell lung cancer. Mayo Clin Proc. 2000; 75: 796-801.
19
20
21 16. Fernandez-Villar A, Botana M, Leiro V, et al. Validity and reliability of transbronchial
22 needle aspiration for diagnosing mediastinal adenopathies. BMC Pulm Med. 2010; 10: 24.
23
24
25 17. Sharafkhaneh A, Baaklini W, Gorin AB, et al. Yield of transbronchial needle aspiration in
26 diagnosis of mediastinal lesions. Chest. 2003; 124: 2131-2135.
27
28
29 18. Pasko E, Serafin-Bromblik J, Piekorz W, et al. Combined endobronchial and endoscopic
30 ultrasound-guided needle aspiration performed by single ultrasound bronchoscopes routine
31 videobronchoscopy for diagnosis of advanced lung cancer – a prospective study. Eur Respir J.
32 2016; 48: 2034.
33
34
35 19. Verma A, Jeon K, Koh WJ, et al. Endobronchial ultrasound-guided transbronchial needle
36 aspiration for the diagnosis of central lung parenchymal lesions. Yonsei Med J. 2013; 54:
37 672-678.
38
39
40 20. Tournoy KG, Rintoul RC, van Meerbeeck JP, et al. EBUS-TBNA for the diagnosis of
41 central parenchymal lung lesions not visible at routine bronchoscopy. Lung Cancer. 2009;
42 63: 45-49.
43
44
45 21. Zhao H, Xie Z, Zhou ZL, et al. Diagnostic value of endobronchial ultrasound-guided
46 transbronchial needle aspiration in intrapulmonary lesions. Chin Med J. 2013; 126: 4312-
47 4315.
48
49
50 22. Oki M, Saka H, Ando M, et al. Endoscopic ultrasound-guided fine needle aspiration and
51 endobronchial ultrasound-guided transbronchial needle aspiration: Are two better than one
52 in mediastinal staging of non-small cell lung cancer? J Thorac Cardiovasc Surg. 2014;
53 148: 1169-1177.
54
55
56 23. Wallace MB, Pascual JM, Raimondo M, et al. Minimally invasive endoscopic staging of
57 suspected lung cancer. JAMA. 2008; 299: 540-546.
58
59
60

- 1
2
3 24. Madan K, Mohan A, Ayub II, et al. Initial experience with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) from a tuberculosis endemic population. *J Bronchol Interv Pulmonol*. 2014; 21: 208-214.
- 4
5
6
7
8 25. Lange T, Kunzendorf F, Pfeifer M, et al. Endobronchial ultrasound-guided transbronchial needle aspiration in routine care-plenty of benign results and follow-up tests. *Int J Clin Pract*. 2012; 66: 438-445.
- 9
10
11
12
13 26. Fournier C, Hermant C, Gounant V, et al. Diagnostic of mediastinal lymphadenopathy in extrathoracic cancer: a place for EBUS-TBNA in real life practice? *Respir Med Res*. 2019; 75: 1–4.
- 14
15
16
17
18 27. Murthi M, Donna E, Arias S, et al. Diagnostic Accuracy of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Real Life. *Front Med (Lausanne)*. 2020; 7:118.
- 19
20
21
22
23
24
25

26
27 Table 1. The results of varies techniques during bronchoscopy in the diagnosis of individual pathomorphological types of lung cancer depending on place of collecting the material and nodal station.

28
29
30
31

Material	SCLC	Adenocarcinoma	Squamous cell carcinoma	NOS	Total lung cancer
EBUS-TBNA/EUS-FNA of lymph nodes	250 (27.7%)	331 (36.7%)	209 (23.1%)	114 (12.5%)	904 (100%)
EBUS-TBNA/EUS-FNA of tumor	88 (24.7%)	94 (25.8%)	135 (37.2%)	44 (12.3%)	361 (100%)
EBUS-TBNA/EUS-FNA metastases to adrenal gland	3 (42.9%)	1 (14.3%)	2 (28.6%)	1 (14.3%)	7 (100%)

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Forceps biopsy of tumor	156 (22%)	163 (25%)	270 (41.5%)	62 (9.5%)	651 (100%)
-------------------------------	-----------	-----------	-------------	--------------	------------

Figure 1. Results of pathomorphological examination carried out on material obtained from 5279 bronchoscopies (entire study population)

Figure 2. The incidence of individual pathomorphological types of LC in the entire study group of lung cancer patients


Figure 3. The incidence of individual pathomorphological types of LC according to the gender of patients with lung cancer

Figure 4. Percentage of patients with different types of lung cancer detected in materials collected with different bronchoscopic techniques. Frequency of different types of lung cancer was calculated in the whole group of patients undergoing a given bronchoscopic procedure (100%), which resulted in the diagnosis of lung cancer




108x60mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




296x209mm (300 x 300 DPI)



296x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



296x209mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	8

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4				
5	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
6	Discussion			
7	Key results	18	Summarise key results with reference to study objectives	9
8	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
9	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11
10	Generalisability	21	Discuss the generalisability (external validity) of the study results	12
11	Other information			
12	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Observational cross-sectional study of 5279 bronchoscopy results for the practical effectiveness of various biopsy techniques in the diagnosis of lung diseases with particular emphasis on lung cancer

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-043820.R3
Article Type:	Original research
Date Submitted by the Author:	28-Jun-2021
Complete List of Authors:	Błach, Justyna; Medical University of Lublin, Frąk, Małgorzata; Medical University of Lublin Krawczyk, Pawel; Medical University of Lublin Pankowski, Juliusz; Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska Pankowski, Adam; SilverSoft Buczowski, Jarosław; Medical University of Lublin Szlubowski, Artur; Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska Siwiec, Jan; Medical University of Lublin Krudyś, Piotr; Izer-Med Michnar, Marek; Medical University of Lublin Kieszko, Robert; Medical University of Lublin Milanowski, Janusz; Medical University of Lublin
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Oncology
Keywords:	Bronchoscopy < THORACIC MEDICINE, Respiratory tract tumours < ONCOLOGY, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Observational cross-sectional study of 5279 bronchoscopy results for the practical**
4 **effectiveness of various biopsy techniques in the diagnosis of lung diseases with**
5 **particular emphasis on lung cancer**
6
7
8
9

10 Justyna Błach^{1,2*}, Małgorzata Frąk^{1*}, Paweł Krawczyk¹, Juliusz Pankowski³, Adam
11 Pankowski⁴, Jarosław Buczkowski^{1,5}, Artur Szlubowski^{3,6}, Jan Siwiec¹, Piotr Krudys⁶, Marek
12 Michnar¹, Robert Kieszko¹, Janusz Milanowski¹
13
14

15 * authors equally contributing
16
17

- 18
19
20 1. Department of Pneumonology, Oncology and Allergology, Medical University of Lublin,
21 20-954 Lublin; Poland
22
23 2. Department of Clinical Immunology, Medical University of Lublin, 20-954 Lublin; Poland
24
25 3. Specialist Hospital for Lung Diseases "Rebirth" Klara Jelska, 34-500 Zakopane, Poland
26
27 4. SilverSoft, Warszewska 64/1, 72-004 Pilchowo, Szczecin, Poland
28
29 5. Department of Lung Diseases and Intensive Care, Independent Public Provincial John of
30 God Hospital in Lublin, 20-400 Lublin, Poland
31
32 6. Izerski Pulmonology and Chemotherapy Center "IZER-MED", 58-580 Szklarska Poręba,
33 Poland
34
35
36
37
38
39
40
41

42 Short title: **The yield of bronchoscopy in the diagnosis of lung cancer**

43 **Corresponding author:**

44 Justyna Błach MD
45

46 Department of Pneumonology, Oncology and Allergology
47

48 Medical University of Lublin, Poland
49

50 Jaczewskiego 8, 20-954 Lublin, Poland
51

52 tel. +48 81 724 42 93
53

54 e-mail: justynablach91@gmail.com
55
56
57
58
59
60

Abstract

Introduction

Bronchoscopy is the main method in the diagnosis of various lung diseases. Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is the most modern bronchoscopic technique useful in diagnosis and staging of lung cancer.

Objectives

The aim of the study was to assess the yield of bronchoscopy in patients with suspected various respiratory diseases including lung cancer. In particular, we examined the efficiency of different biopsy techniques in the diagnosis of lung cancer in correlation with its localization and pathomorphological type.

Patients and Methods

The results of pathomorphological examinations from 5279 bronchoscopies performed in 2016-2018 were analyzed. The material was collected with endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA), endoscopic ultrasound guided fine needle aspiration (EUS-FNA) and endobronchial forceps biopsy. Clinical and demographic factors were analyzed using the Fisher χ^2 test.

Results

5279 patients were diagnosed due to various respiratory symptoms. Lung cancer was confirmed in 36.42% of patients. 40.81% of patients had no definitive pathomorphological diagnosis. Among patients with lung cancer, the most frequent diagnosis was non-small cell lung cancer: squamous cell lung cancer (SCC) - 32.07% and adenocarcinoma (AC) - 30.61%, then small cell lung cancer (SCLC) - 25.83% and not otherwise specified non-small cell lung cancer (NSCLC NOS) - 11.49%. Diagnosis of SCC was obtained significantly more often ($\chi^2=43.143$, $p<0.000001$) by forceps biopsy (41.09%) than by EBUS-TBNA/EUS-FNA (26.62%). On the contrary, diagnosis of AC or NSCLC NOS was significantly more often ($\chi^2=20.394$, $p<0.000007$ and $\chi^2=3.902$, $p<0.05$, respectively) observed in EBUS-TBNA/EUS-FNA (34.31% and 12.6%) than in endobronchial biopsies (24.52% and 9.64%).

Conclusions

The use of bronchoscopy in the diagnosis of various lung diseases is vital but also has many limitations. Effectiveness of EBUS-TBNA and endobronchial forceps biopsy in diagnosis of lung cancer is strongly affected by tumor localization and type of cancer.

Key words: lung cancer; bronchoscopy; endobronchial biopsy; EBUS-TBNA; EUS-FNA

Article summary

Strengths and limitations of this study

1. 5 279 patients were enrolled to the study group which makes it one of the largest studies in the world with assessment of bronchoscopy effectiveness in routine clinical practice.
2. We analyzed bronchoscopies performed in 2016-2018 in a few Polish medical centers across the country, in a diversified population which ensures a high level of generalisability.
3. The study is an important contribution to the epidemiological data of advanced lung cancer in Poland.
4. Bronchoscopies were performed by 8 different bronchoscopists. This fact may cause human-dependent variation in results.
5. Results of pathomorphological assessment of the material obtained during single bronchoscopy was analyzed. Patients without diagnosed disease in the bronchoscopic material underwent further diagnostics using other methods or in other centers. Therefore, we were unable to report a definitive diagnosis in patients with inconclusive results of diagnostic procedures.

Introduction

Epidemiological analyses indicate that lung cancer (LC) is the most common cause of cancer-related deaths. It is usually diagnosed in an unresectable, advanced stage. [1, 2] Lung cancer is the most common cancer in men and the third most common in women. In 2018, there were more than 2 million new cases of lung cancer worldwide. [3]

In the United States from 2004 to 2009, a total of 1,096,276 lung cancer cases were diagnosed and reported. This American study investigated the histologic type of lung cancer and demographic characteristics of the patients. The incidence of individual types of LC was as follows: small cell lung cancer (SCLC) – 14.9%, squamous cell carcinoma (SCC) – 21.9%, adenocarcinoma (AC) – 37.1% and large cell carcinoma (LCC) – 3.2% of cases. [4]

It is difficult to obtain accurate epidemiological data on the occurrence of individual pathomorphological types of advanced LC in Poland. Up to date, no epidemiological studies have been conducted on a sufficiently large group of patients with advanced lung cancer to obtain reliable results. Statistics on pathomorphological diagnoses of lung cancer in material from bronchoscopy have not been conducted so far. In Poland, the main source of such data is the National Lung Cancer Registry which only contains details about patients undergoing surgery in earlier stages of the disease. There were 17,783 patients diagnosed and operated in Polish thoracic surgery centers and registered in the National Lung Cancer Registry in the years

1
2
3 2014-2018. This group includes: 48.7% of patients with AC, 40.8% of patients with SCC,
4 6.45% of patients with LCC, 2.1% of patients with adenosquamous cell carcinoma, 1.05% of
5 patients with SCLC and 0.9% of patients with non-otherwise specified (NOS) non-small cell
6 lung cancer (NSCLC). This material included low percentage of patients with SCLC (usually
7 an inoperable type of lung cancer) and patients with NSCLC-NOS (large surgical material is
8 easier for pathomorphological examination which is a factor of reducing misdiagnosis).
9 According to IASLC (International Association for the Study of Lung Cancer)
10 recommendations, large cell carcinoma should be diagnosed only in surgical materials extracted
11 from the entire resected tumor. [5] Therefore, this type of cancer was recorded in surgical
12 pathology in non-advanced NSCLC patients and almost absent in patients with advanced lung
13 cancer diagnosed with tumor biopsy. [2]

22 Due to different locations of tumor types in the lungs or metastatic lymph nodes, varied
23 approaches are required to cancer diagnosis. The peripheral location is characteristic for AC,
24 while squamous and small cell carcinomas most often are located centrally. Bronchoscopy is
25 an appropriate method for detecting LC and the endobronchial ultrasound-guided with
26 transbronchial needle aspiration (EBUS-TBNA) procedure has an essential role in the
27 investigation of lung cancer. If the tumor is centrally located and infiltrated the bronchus, the
28 most optimal procedure seems to be the endobronchial biopsy using a brush or forceps. In
29 contrast, adenocarcinoma frequently metastasizes to the mediastinal lymph nodes, which may
30 be available on EBUS-TBNA or EUS-FNA procedures.

37 Metastasis to mediastinal lymph nodes is typical for each of types of lung cancer. We
38 distinguish compartments of the mediastinal lymph nodes: superior mediastinal nodes (stations
39 2, 3 and 4), aortic nodes (stations 5 and 6), inferior mediastinal nodes (stations 7, 8, 9), hilar
40 and interlobar lymph nodes (stations 10 and 11) and peripheral lymph nodes (station 12 for
41 lobar nodes, station 13 for segmental nodes and station 14 for subsegmental nodes). EBUS-
42 TBNA is most often used in diagnosis of superior mediastinal nodes, station 7 of inferior
43 mediastinal nodes and stations 10, 11, 12 lymph nodes. EUS-FNA is preferred in diagnosis of
44 superior mediastinal nodes and stations 7, 8 and 9 of inferior mediastinal nodes. Moreover EUS-
45 FNA is used for sampling subphrenic lymph nodes and metastases in liver and left adrenal
46 gland. Both methods – EBUS-TBNA and EUS-FNA are preferred for mediastinal lymph nodes
47 assessment for evaluation of N-stage in NSCLC patients. [6] These two methods could be used
48 in sampling visible tumors localized in central airways but also peripherally to the main bronchi,
49 i.e. in lobar or even segmental bronchi.

1
2
3 Lung cancer staging is initially assessed through imaging studies. Normal mediastinum
4 lymph nodes are defined below 10 mm in computed tomography (CT). Such a size of these
5 lymph nodes suggests the N0 clinical stage. Currently, sampling for N0 nodes is not
6 recommended, while surgery is the primary treatment method for N0/N1 stage of lung cancer.
7 However, everyday practice shows that it is worth collecting non-enlarged nodes for
8 pathomorphological examination, because cancer cells are often found in such nodes. [7,8]
9

10
11
12 The sensitivity of detecting lung cancer using different bronchoscopy methods varies
13 from 34% to 88% depending on the size and location of the tumor and preliminary diagnosis of
14 the patients. [9] Meta-analysis of 18 studies which included a total of 1,201 LC patients was
15 performed for assessment of sensitivity and specificity of ultrasound-guided fine needle
16 aspiration in mediastinal staging of lung cancer. Authors showed sensitivity of 83% (range 45-
17 100%) and specificity of 97% (range 88-100%) of these methods. [10] In eight studies limited
18 to patients with enlarged mediastinal lymph nodes seen on CT, sensitivity was 90% (95% CI:
19 84 to 94%) and specificity was 97% (95% CI: 95 to 98%). In patients without enlarged
20 mediastinal lymph nodes visible on CT, the overall sensitivity was 58% (95% CI: 39-75%).
21 Therefore, the use of EBUS-TBNA increases the accuracy in the estimation of the stage of lung
22 cancer and may radically influence the further treatment of the patient and the selection of the
23 treatment methods. EUS-FNA enables confirming the presence of distant metastases, which has
24 a decisive impact on therapeutic decisions. However, all false negative results delay cancer
25 diagnosis and force the repetition of diagnostic procedures including surgery. Earlier detection
26 of lung cancer gives patients the chance for better treatment. [11]
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Aim**

42
43
44 The objective of our study was a descriptive analysis of lung diseases diagnoses,
45 especially lung cancer, established by various bronchoscopic procedures. We devoted special
46 attention to the possibility of diagnosis of individual pathomorphological types of LC with
47 various techniques used for collecting materials during bronchoscopy.
48
49
50
51
52
53
54

55 **Material and methods**

56
57 In our observational cross-sectional study, we analyzed the results of
58 pathomorphological examination carried out on the material obtained during 5279
59 bronchoscopies performed in 2016-2018. Those bronchoscopies were performed in three Polish
60

1
2
3 pulmonology departments. The study included 1892 women and 3387 men, with median age
4 of 65 years.

5
6 The study was retrospective and relied fully on the analysis of documents gathered, thus
7 eliminating the need for collaboration between patients and researchers. No patients were
8 enrolled specifically to carry out this study.

9
10
11 Various diseases of the respiratory system were indication for bronchoscopy: 3127
12 (59.2%) patients had suspicion of chest tumor in computed tomography, 882 (16.7%) patients
13 demonstrated hilar lymphadenopathy, 205 (3.9%) patients had suspicion of sarcoidosis and 20
14 (0.4%) patients had suspicion of pulmonary fibrosis. Other indications for bronchoscopy
15 occurred in 1045 (19.8%) patients (e.g. suspicion of tuberculosis, chronic cough, hemoptysis,
16 etc.). In patients with suspected cancer, samples of the tissue were acquired through
17 bronchoscopy and the technique was chosen in compliance with tumor or metastatic lymph
18 node's location as it is described in the introduction. Forceps biopsies were performed using
19 Olympus BF-1T180 and Pentax EB-1970K bronchoscopes, EBUS-TBNA – using Olympus
20 BF-UC180F and Pentax EB-1970UK bronchoscopes (22-gauge needles), and EUS-FNA –
21 using Olympus GF-UCT180 endoscope. Premedication for bronchoscopy was under local or
22 general anesthesia, depending on the situation.

23
24
25 Samples underwent pathomorphological examination which included hematoxylin-
26 eosin (H&E) staining, mucicarmine staining and immunohistochemistry (IHC) examination,
27 such as staining of TTF-1 (thyroid transcription factor 1) and p63/p40. Samples diagnosed with
28 non-squamous NSCLC were in-depth reported and underwent molecular testing for the
29 presence of *EGFR* gene mutation by real-time PCR technique (RT-PCR), *ALK* gene
30 rearrangement and PD-L1 expression by IHC. PD-L1 expression was also assessed in SCC
31 patients. Large cell carcinoma (LCC) of the lung according to the 2015 World Health
32 Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart cannot
33 be diagnosed in small specimens and aspiration biopsy materials. The diagnosis of LCC can
34 only be made in the postoperative material. Therefore, there were no patients diagnosed with
35 LCC in our study. Such patients were included in the group of patients diagnosed with NSCLC
36 NOS. Chromogranin and synaptophysin was used in IHC examination of neuroendocrine
37 tumors (small cell lung cancer or NSCLC NOS). All the centers participating in the study used
38 these same procedures described above.

39
40
41 After receiving the diagnosis, we selected a population of patients with lung cancer and
42 divided them into groups of patients with different cancer types detectable with bronchoscopic
43 procedure (squamous cell lung cancer, adenocarcinoma, large cell carcinoma, not otherwise
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 specified NSCLC, and small cell lung cancer). Then, we assessed the prevalence of different
4 types of LC in the materials obtained with various bronchoscopic procedures.
5

6 Clinical and demographic factors were analyzed using the Pearson's Chi-square test. P-
7 values below 0.05 were considered significant. The percentages reflect the relative number of
8 all lung cancer patients diagnosed with a particular procedure. We only analyzed the results of
9 the first-time bronchoscopy, that could be nondiagnostic. The evaluation of relative diagnostic
10 yield (sensitivity) of different bronchoscopic procedures could not be done because, in our
11 study, it was not possible to verify the final diagnosis of patients in the materials collected
12 during the next bronchoscopy or another procedures (this applies mainly to patients with lung
13 tumor or hilar lymphadenopathy). The following diagnostic procedures were carried out in
14 various clinical centers throughout Poland. Therefore, we were unable to verify the diagnoses
15 obtained later.
16

17 Patient and Public involvement statement: Patients were not involved in research.
18

19 The protocol of the study was approved by the Committee of Ethics and Research at the
20 Medical University of Lublin (KE-0254/5/2018).
21

22 **Results**

23 In 3565 (67.5%) patients, EBUS-TBNA and transesophageal EUS-FNA was performed
24 and cytological material was archived in a cellblock. In 1346 (25.5%) patients, EBUS-TBNA
25 (without EUS-FNA) was the only diagnostic procedure. In the remaining patients, EBUS-
26 TBNA was supplemented by EUS-FNA. There were no patients in whom EUS-FNA would be
27 the only diagnostic method. 1714 (32.5%) patients had non-ultrasound-guided bronchoscopy
28 with the forceps biopsy of endobronchial lesions allowing to obtain a small histological
29 specimen.
30

31 Lung cancer was confirmed in a group of 1923 (36.42%) patients, including 1280 men
32 and 643 women. Reactive lymph nodes were found in 16.06% of the patients, sarcoidosis was
33 diagnosed in 4.13%, idiopathic pulmonary fibrosis – in 0.19%, metastases to the lungs from
34 other organs – in 2.39% of the patients. 40.81% of the patients had no definitive diagnosis
35 (Figure 1). Lung cancer was confirmed in 51% of patients with suspected tumor in computed
36 tomography. While, in the group of patients with hilar lymphadenopathy, lung cancer was
37 diagnosed in only 10.1% of cases.
38

39 Among those with lung cancer, squamous cell carcinoma (32.07%) was most often
40 diagnosed, then adenocarcinoma (30.61%), small cell lung cancer (25.83%) and NSCLC-NOS
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (11.49%) (Figure 2). SCLC and AC were significantly more frequent ($\chi^2 = 8.649$, $p = 0.0033$
4 and $\chi^2 = 21.128$, $p < 0.000005$, respectively) in women (29.97% and 37.42% of women with
5 lung cancer) than in men (23.75% and 27.19% of male patients with lung cancer). Squamous
6 cell carcinoma appeared significantly more often ($\chi^2 = 41.881$, $p < 0.000001$) among male
7 (36.95%) than among female (22.36%) patients with lung cancer (Figure 3). SCC was
8 significantly more often ($\chi^2 = 4.17$, $p = 0.041$) diagnosed in the group of patients older than 65
9 years than in younger patients. Other pathomorphological types of lung cancer occurred with
10 similar frequency in these two age groups.
11

12
13
14
15
16
17 Endobronchial biopsies significantly more often ($\chi^2 = 7.566$, $p = 0.0059$) provided
18 material for the diagnosis of lung cancer than the EBUS-TBNA and EUS-FNA procedures.
19 42.35% of endobronchial biopsies and 33.6% of TBNA and FNA provided material sufficient
20 to diagnose lung cancer. Fine needle biopsy of lymph nodes enabled the diagnosis of lung
21 cancer in 29.2% of cases, fine needle biopsy of lung tumor – in 66.6% of cases, and forceps
22 biopsy of bronchial mucosa lesions – in 48.2% of cases. These differences were statistically
23 significant.
24

25
26
27
28
29 Among patients with lung cancer, TBNA or FNA compared to endobronchial biopsies
30 gave a similar result ($\chi^2 = 0.656$, $p = 0.418$) in detection of SCLC (26.5% vs. 24.8%). On the
31 other hand, the diagnosis of AC and NSCLC-NOS was obtained significantly more frequently
32 ($\chi^2 = 20.394$, $p = 0.000006$ and $\chi^2 = 3.902$, $p = 0.0482$) in EBUS-TBNA and EUS-FNA
33 compared to endobronchial biopsies (34.3% vs. 24.52% and 12.6% vs. 9.6%, respectively).
34 SCC, among other lung cancer types detected by bronchoscopy, was diagnosed in 41.77% in
35 materials obtained by forceps biopsy and only in 26.62% in materials with EBUS-TBNA or
36 EUS-FNA ($\chi^2 = 43.143$, $p < 0.000001$), which was directly related to the more frequent central
37 location and bronchial infiltration of this type of tumor. Computed tomography showed that in
38 79% of SCC patients the tumor was centrally located in the large bronchi. The analysis of
39 bronchoscopic images showed that tumor deformed the bronchial mucosa or showed
40 endobronchial growth in 67% of SCC patients. (Figure 4). Table 1 shows the results of
41 bronchoscopy procedures in the diagnosis of individual pathomorphological types of lung
42 cancer depending on place of collecting the material.
43
44
45
46
47
48
49
50
51
52
53

54 Discussion

55
56
57 Our study on the results of EBUS-TBNA/EUS-FNA and forceps biopsy in obtaining
58 materials for the diagnosis of various lung diseases is among the largest worldwide. The study
59 points to numerous problems arising from the use of these techniques in routine clinical
60

1
2
3 practice. We are aware of the many limitations of our study. First, we cannot determine the
4 sensitivity and specificity of our methods, because it was not possible to determine the final
5 diagnosis in such a large group of patients (5 279 cases). In addition, we could not distinguish
6 between material collected by EBUS-TBNA and EUS-FNA. We do not know how many lung
7 cancer patients were diagnosed only in the material from EBUS-TBNA or only in the material
8 from EUS-FNA, or in both types of these materials. We also do not know the number of biopsies
9 performed during one bronchoscopy. This data is missing from the results of the
10 pathomorphological examination that we analyzed. Thirdly, diagnosis of large cell carcinoma
11 was not possible in small specimens (LCC was probably qualified to the NSCLC-NOS group).
12 A limitation of our study was also the lack of detailed clinical and radiological characteristics
13 of all patients who underwent bronchoscopy procedures.
14
15

16
17 However, we found that advanced small cell lung cancer may be more common in
18 Poland than previously thought. This tumor is characterized by rapid growth and metastases,
19 therefore, more often it could be diagnosed in advanced stages using bronchoscopic techniques.
20 SCLC diagnosis in EBUS-TBNA/EUS-FNA of lymph nodes and endobronchial biopsy occurs
21 at the same frequency. Furthermore, the difference in the percentage of patients with squamous
22 cell carcinoma and adenocarcinoma diagnosed with endobronchial biopsies and TBNA or FNA
23 is noteworthy. In our study, most patients with adenocarcinoma were diagnosed with EBUS-
24 TBNA or EUS-FNA of lymph nodes, while patients with squamous cell carcinoma were
25 diagnosed more often based on examination of material from endobronchial biopsy (forceps
26 biopsy). Patients in cohort with squamous cell carcinoma were more likely to have
27 endobronchial disease accessible by forceps. Therefore we could not ascertain that
28 endobronchial biopsy is more effective for diagnosis of squamous cell lung cancer as there was
29 no comparison to EBUS-TBNA and EUS-FNA for those patients. Thus, we point to the problem
30 that results of bronchoscopic procedures depends on the location of the primary tumor and the
31 presence of metastases in the lymph nodes.
32
33

34
35 Schmid-Bindert et al. showed how often they detected different pathomorphological
36 types of lung cancer using various bronchoscopic methods. Small biopsies were collected by
37 three different methods: forceps biopsy (44.6%), EBUS-TBNA (32.7%), and CT-guided core
38 biopsy (22.8%). 38% of adenocarcinoma, 51% of squamous cell carcinoma and 11% of NSCLC
39 NOS were diagnosed using forceps biopsy. EBUS-TBNA results were as follows: 45% of
40 adenocarcinoma, 30% of squamous cell carcinoma and 24% of NSCLC NOS. [12]
41
42

43
44 Many authors emphasize that the diagnosis of NSCLC NOS is the most common in the
45 case of material obtained from EBUS-TBNA. Esterbrook et al. found that NSCLC-NOS rate
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 was 20.8% in EBUS-TBNA samples. Similar results were achieved by Navani et al. In group
4 of 774 patients with known or suspected lung cancer, 23% of patients had a final diagnosis of
5 NSCLC NOS. [13, 14] Our study confirmed the high percentage of NSCLC NOS patients
6 diagnosed with EBUS-TBNA procedures. Endobronchial biopsy was less likely to provide a
7 diagnosis of NSCLC NOS.
8
9

10
11
12 Chin et al. reported that EBUS-TBNA is the most sensitive diagnostic method for SCLC
13 detection, because it allows to sample specimens from mediastinal as well as submucosal
14 lesions. They also mentioned that the quality of specimens obtained by needle aspiration is
15 better than by forceps biopsies, which may contain crushed artifacts. [15] In addition, other
16 studies noticed that the sensitivity of EBUS-TBNA for SCLC detection was higher than for
17 NSCLC diagnosis. [16, 17] Our findings confirmed the above statements. The majority of
18 SCLC cases were diagnosed with EBUS-TBNA. Three SCLC patients were diagnosed from
19 metastatic lesions in the adrenal gland using transesophageal EUS-FNA.
20
21
22
23
24

25
26 Many authors raise the problem that forceps biopsy has low sensitivity in the diagnosis
27 of lung cancer. Forceps biopsy has a diagnostic yield ranging between 65-82%. In preliminary
28 study by Pasko et al. conducted in 212 patients with lung cancer suspicion, authors compared
29 sensitivity and accuracy of routine bronchoscopy techniques: endobronchial biopsy, EBUS-
30 TBNA, and combination of EBUS-TBNA and EUS-FNA. Sensitivity and accuracy of
31 endobronchial biopsy vs EBUS-TBNA vs combination of transbronchial biopsies were 43% vs
32 44.3% vs 93.7% and 93.8% vs 94.7% and 94.8%, respectively. This demonstrates high
33 usefulness of the combination of EBUS-TBNA and EUS-FNA in the diagnosis of lung cancer
34 [18]. Verma et al. demonstrated sensitivity of EBUS-TBNA in cancer diagnosis of 91.4% in
35 small group of 37 patients with lesions located adjacent to the trachea or lesions located adjacent
36 to the main bronchi. [19] Tournoy et al. indicated that EBUS-TBNA has a sensitivity of 82%
37 and low negative predictive value (23%). [20] The similar results were received by Zhao et al.
38 for lesions located near the central airways. [21] Oki et al. showed that the combined endoscopic
39 method with EBUS-TBNA and EUS-FNA with a single bronchoscope gives better results in
40 staging of NSCLC, than each technique alone. However, they mentioned that significant
41 number of patients had false-negative EBUS-TBNA and EUS-FNA results. Moreover Oki et
42 al. suggested that very important issue is bronchoscopists experience, which may cause
43 differences in the results. [22] On the other hand, Wallace et al. showed a EBUS-TBNA
44 sensitivity of only 69% in a group of 150 patients with lung cancer suspicion. [23]
45
46
47
48
49
50
51
52
53
54
55
56
57

58
59 Despite relatively low negative predictive value of EBUS-TBNA, there is an indication
60 to perform other procedures (e.g., surgical procedures) for final diagnosis in a significant group

1
2
3 of patients. In our study, 56.9% of patients who underwent bronchoscopy did not receive a
4 definitive diagnosis of the diseases and they have been subjected to other diagnostic procedures
5 or observations. We showed the results of all performed bronchoscopies and three different
6 methods of material collection (endobronchial biopsy and combination EBUS-TBNA and EUS-
7 FNA). Moreover, unselected and heterogeneous patients were recruited in three different
8 hospitals that employ a total of 8 bronchoscopists. In most studies, the evaluation of the
9 usefulness of EBUS-TBNA and EUS-FNA for detecting malignancy was conducted in selected
10 patients with high clinical suspicion of the tumor. Small, preselected groups of patients with
11 high risk of lung cancer could be the reason of the low negative predictive value of
12 bronchoscopic procedures in these studies. Thus, these observations may not reflected the real
13 clinical situation.
14
15
16
17
18
19
20
21

22 In studies where population was heterogenic regarding the disease (lung cancer,
23 sarcoidosis, tuberculosis), EBUS-TBNA had diagnostic value only in 60-75% of patients. [24]
24 Lange et al. showed diagnostic results of EBUS-TBNA in only 61.4% of unselected patients
25 undergoing routine diagnostic procedures. [25] Fournier et al. examined 185 patients with
26 extrathoracic malignancy and mediastinal lymphadenopathy in real life practice.
27 Pathomorfological types of malignancy were successfully identified using EBUS-TBNA in
28 only 93 patients (50.3%). The diagnostic sensitivity, specificity, negative predictive value, and
29 positive predictive value were 68.4%, 100%, 53.3%, and 100%, respectively. [26] Murthi et al
30 conducted research comparing the accuracy of EBUS-TBNA to surgery in diagnosis of hilar
31 and mediastinal pathologies. EBUS-TBNA for all pathologies had an accuracy of 81.2% and
32 sensitivity of 55.1%. [27]
33
34
35
36
37
38
39
40
41
42

43 **Conclusions**

44 Comparing all these data, we could conclude that bronchoscopy is vital but not an ideal
45 technique in the routine diagnosis of respiratory diseases. Our study showed that 41% of
46 bronchoscopy materials were insufficient to perform reliable pathomorphological examination.
47 This mainly concerned patients with suspected lung tumor or lymphadenopathy. The use of
48 brush biopsy, forceps biopsy, bronchoaspirate analysis EBUS-TBNA and EUS-FNA
49 simultaneously, if desired, was of the highest diagnostic value. However, sometimes this fails
50 and bronchoscopy must be repeated, or thoracic procedures (e.g. mediastinoscopy or
51 thoracoscopy) must be performed. We found that the EBUS-TBNA value in daily clinical
52 practice differed from that in clinical trials. Therefore, precise estimation of the frequency of
53 individual pathomorphological types of lung cancer, based on material obtained
54
55
56
57
58
59
60

1
2
3 bronchoscopically, is not possible. However, EBUS-TBNA plays an essential role in staging of
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

bronchoscopically, is not possible. However, EBUS-TBNA plays an essential role in staging of
invasive lung cancer. Therefore, its value in the diagnosis of lung cancer is not limited to
demonstrating the presence of cancer type, but, above all, to determining the extent of the
disease and qualification for appropriate treatment. It seems that the incidence of lung cancer
with a typical peripheral localization (adenocarcinoma) may be underestimated in comparison
to the incidence of lung cancer with a typical central localization (squamous cell carcinoma,
SCLC), when bronchoscopy is used as the primary diagnostic method.

Authorship contribution statement:

Conception and design of the study: JB, MF, PK, JP. Administrative support: PK, JP, AP, JB,
AS, JS, MM, PK, RK, JM. Provision of study material or patients: JP, AP, JB, AS, JS, MM,
PK, RK, JM. Collection and assembly of data: JB, MF, PK, JP, AP, JB, AS, JS, MM, PK, RK.
Data analysis and interpretation: JB, MF, PK. Manuscript writing: JB, MF, PK. All authors
gave final approval of the published manuscript.

Data Availability Statement:

The data that supports the findings of this study are available from the corresponding author
upon reasonable request.

Conflicts of Interest:

The authors declare no potential conflicts of interest.

Fundings:

This research did not receive any specific grant from funding agencies in the public,
commercial, or not-for-profit sectors.

Acknowledgements:

The authors would like to thank prof. Tadeusz Orłowski and prof. Maciej Krzakowski for
their helpful comments that improved the research and manuscript.

References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. CA Cancer J Clin. 2017; 67: 7-30.

- 1
2
3 2. Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health
4 Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. *Thorac*
5 *Oncol.* 2015; 10: 1240-1242.
- 6
7
8 3. Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN
9 estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA*
10 *Cancer J Clin.* 2018; 68: 394-424.
- 11
12 4. Houston KA, Henley SJ, Li J, et al. Patterns in lung cancer incidence rates and trends by
13 histologic type in the United States, 2004-2009. *Lung Cancer.* 2014; 86: 22-28.
- 14
15 5. Zugazagoitia J, Enguita AB, Nuñez JA, Iglesias L, Ponce S. The new IASLC/ATS/ERS
16 lung adenocarcinoma classification from a clinical perspective: current concepts and
17 future prospects. *J Thorac Dis.* 2014;6(Suppl 5): S526-S536
- 18
19 6. Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and oesophageal
20 endosonography for the diagnosis and staging of lung cancer. European Society of
21 Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European
22 Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). *Eur*
23 *Respir J.* 2015; 46: 40-60.
- 24
25 7. Gomez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M et al. Incidence of occult
26 mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative
27 uptake of positron emission tomography/computer tomography scan. *Eur J Cardiothorac*
28 *Surg.* 2010; 37: 1168-1174.
- 29
30 8. Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Problems in diagnosis and surgical
31 management of clinical N1 non-small cell lung cancer. *Ann Thorac Surg.* 2005; 79: 1682-
32 1685
- 33
34 9. Rivera MP, Wahidi MM, Mehta AC. Establishing the diagnosis of lung cancer: Diagnosis
35 and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-
36 based clinical practice guidelines. *Chest.* 2013; 143: 142-165.
- 37
38 10. Micames CG, McCrory DC, Pavey DA, et al. Endoscopic ultrasound-guided fine-needle
39 aspiration for non-small cell lung cancer staging: A systematic review and meta-analysis.
40 *Chest.* 2007. 131: 539-548.
- 41
42 11. Sutedja TG, Codrington H, Risse EK, et al. Autofluorescence bronchoscopy improves
43 staging of radiographically occult lung cancer and has an impact on therapeutic strategy.
44 *Chest.* 2001. 120: 1327-1332.
- 45
46 12. Schmid-Bindert G, Wang Y, Jiang H, et al. EBUS-TBNA provides highest RNA yield for
47 multiple biomarker testing from routinely obtained small biopsies in non-small cell lung
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 cancer patients - a comparative study of three different minimal invasive sampling
4 methods. *PLoS One*. 2013; 8: 77948.
5
6
7 13. Navani N, Brown JM, Nankivell M, et al. Suitability of EBUS-TBNA specimens for
8 subtyping and genotyping of NSCLC: a multi-centre study of 774 patients. *Am J Respir*
9 *Crit Care Med*. 2012; 185: 1316-1322.
10
11 14. Esterbrook G, Anathhanam S, Plant PK. Adequacy of endobronchial ultrasound
12 transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer.
13 *Lung Cancer*. 2013; 80: 30-34.
14
15 15. Chin R Jr, Cappellari JO, McCain TW, et al. Increasing use of bronchoscopic needle
16 aspiration to diagnose small cell lung cancer. *Mayo Clin Proc*. 2000; 75: 796-801.
17
18 16. Fernandez-Villar A, Botana M, Leiro V, et al. Validity and reliability of transbronchial
19 needle aspiration for diagnosing mediastinal adenopathies. *BMC Pulm Med*. 2010; 10: 24.
20
21 17. Sharafkhaneh A, Baaklini W, Gorin AB, et al. Yield of transbronchial needle aspiration in
22 diagnosis of mediastinal lesions. *Chest*. 2003; 124: 2131-2135.
23
24 18. Pasko E, Serafin-Bromblik J, Piekorz W, et al. Combined endobronchial and endoscopic
25 ultrasound-guided needle aspiration performed by single ultrasound bronchoscopes routine
26 videobronchoscopy for diagnosis of advanced lung cancer – a prospective study. *Eur Respir J*.
27 2016; 48: 2034.
28
29 19. Verma A, Jeon K, Koh WJ, et al. Endobronchial ultrasound-guided transbronchial needle
30 aspiration for the diagnosis of central lung parenchymal lesions. *Yonsei Med J*. 2013; 54:
31 672-678.
32
33 20. Tournoy KG, Rintoul RC, van Meerbeeck JP, et al. EBUS-TBNA for the diagnosis of
34 central parenchymal lung lesions not visible at routine bronchoscopy. *Lung Cancer*. 2009;
35 63: 45-49.
36
37 21. Zhao H, Xie Z, Zhou ZL, et al. Diagnostic value of endobronchial ultrasound-guided
38 transbronchial needle aspiration in intrapulmonary lesions. *Chin Med J*. 2013; 126: 4312-
39 4315.
40
41 22. Oki M, Saka H, Ando M, et al. Endoscopic ultrasound-guided fine needle aspiration and
42 endobronchial ultrasound-guided transbronchial needle aspiration: Are two better than one
43 in mediastinal staging of non-small cell lung cancer? *J Thorac Cardiovasc Surg*. 2014;
44 148: 1169-1177.
45
46 23. Wallace MB, Pascual JM, Raimondo M, et al. Minimally invasive endoscopic staging of
47 suspected lung cancer. *JAMA*. 2008; 299: 540-546.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 24. Madan K, Mohan A, Ayub II, et al. Initial experience with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) from a tuberculosis endemic population. *J Bronchol Interv Pulmonol*. 2014; 21: 208-214.
- 4
5
6
7
8 25. Lange T, Kunzendorf F, Pfeifer M, et al. Endobronchial ultrasound-guided transbronchial needle aspiration in routine care-plenty of benign results and follow-up tests. *Int J Clin Pract*. 2012; 66: 438-445.
- 9
10
11
12
13 26. Fournier C, Hermant C, Gounant V, et al. Diagnostic of mediastinal lymphadenopathy in extrathoracic cancer: a place for EBUS-TBNA in real life practice? *Respir Med Res*. 2019; 75: 1–4.
- 14
15
16
17
18 27. Murthi M, Donna E, Arias S, et al. Diagnostic Accuracy of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) in Real Life. *Front Med (Lausanne)*. 2020; 7:118.
- 19
20
21
22
23
24
25

26
27 Table 1. The results of varies techniques during bronchoscopy in the diagnosis of individual pathomorphological types of lung cancer depending on place of collecting the material and nodal station.

28
29
30
31

Material	SCLC	Adenocarcinoma	Squamous cell carcinoma	NOS	Total lung cancer
EBUS-TBNA/EUS-FNA of lymph nodes	250 (27.7%)	331 (36.7%)	209 (23.1%)	114 (12.5%)	904 (100%)
EBUS-TBNA/EUS-FNA of tumor	88 (24.7%)	94 (25.8%)	135 (37.2%)	44 (12.3%)	361 (100%)
EBUS-TBNA/EUS-FNA metastases to adrenal gland	3 (42.9%)	1 (14.3%)	2 (28.6%)	1 (14.3%)	7 (100%)

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Forceps biopsy of tumor	156 (22%)	163 (25%)	270 (41.5%)	62 (9.5%)	651 (100%)
-------------------------	-----------	-----------	-------------	-----------	------------

Figure 1. Results of pathomorphological examination carried out on material obtained from 5279 bronchoscopies (entire study population)

Figure 2. The incidence of individual pathomorphological types of LC in the entire study group of lung cancer patients

Figure 3. The incidence of individual pathomorphological types of LC according to the gender of patients with lung cancer

Figure 4. Percentage of patients with different types of lung cancer detected in materials collected with different bronchoscopic techniques. Frequency of different types of lung cancer was calculated in the whole group of patients undergoing a given bronchoscopic procedure (100%), which resulted in the diagnosis of lung cancer




Figure 1. Results of pathomorphological examination carried out on material obtained from 5279 bronchoscopies (entire study population)

108x60mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. The incidence of individual pathomorphological types of LC in the entire study group of lung cancer patients

296x209mm (300 x 300 DPI)




Figure 3. The incidence of individual pathomorphological types of LC according to the gender of patients with lung cancer

296x209mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Percentage of patients with different types of lung cancer detected in materials collected with different bronchoscopic techniques. Frequency of different types of lung cancer was calculated in the whole group of patients undergoing a given bronchoscopic procedure (100%), which resulted in the diagnosis of lung cancer

296x209mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	6-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6-7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	
		(c) Explain how missing data were addressed	
		(d) If applicable, explain how loss to follow-up was addressed	
		(e) Describe any sensitivity analyses	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	Report numbers of outcome events or summary measures over time	8

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	8
2			(b) Report category boundaries when continuous variables were categorized	
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
4	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
5	Discussion			
6	Key results	18	Summarise key results with reference to study objectives	9
7	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9
8	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-11
9	Generalisability	21	Discuss the generalisability (external validity) of the study results	12
10	Other information			
11	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.